0000943535
false
FY
0000943535
2021-01-01
2021-12-31
0000943535
2022-04-10
0000943535
2021-06-30
0000943535
2021-12-31
0000943535
2020-12-31
0000943535
WHEN:SeriesBConvertiblePreferredStockMember
2021-12-31
0000943535
WHEN:SeriesBConvertiblePreferredStockMember
2020-12-31
0000943535
2020-01-01
2020-12-31
0000943535
us-gaap:PreferredStockMember
2019-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
us-gaap:PreferredStockMember
2019-12-31
0000943535
us-gaap:CommonStockMember
2019-12-31
0000943535
us-gaap:AdditionalPaidInCapitalMember
2019-12-31
0000943535
WHEN:ForeignCurrencyTranslationAdjustmentsMember
2019-12-31
0000943535
us-gaap:RetainedEarningsMember
2019-12-31
0000943535
2019-12-31
0000943535
us-gaap:PreferredStockMember
2020-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
us-gaap:PreferredStockMember
2020-12-31
0000943535
us-gaap:CommonStockMember
2020-12-31
0000943535
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0000943535
WHEN:ForeignCurrencyTranslationAdjustmentsMember
2020-12-31
0000943535
us-gaap:RetainedEarningsMember
2020-12-31
0000943535
us-gaap:PreferredStockMember
2020-01-01
2020-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
us-gaap:PreferredStockMember
2020-01-01
2020-12-31
0000943535
us-gaap:CommonStockMember
2020-01-01
2020-12-31
0000943535
us-gaap:AdditionalPaidInCapitalMember
2020-01-01
2020-12-31
0000943535
WHEN:ForeignCurrencyTranslationAdjustmentsMember
2020-01-01
2020-12-31
0000943535
us-gaap:RetainedEarningsMember
2020-01-01
2020-12-31
0000943535
us-gaap:PreferredStockMember
2021-01-01
2021-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
us-gaap:PreferredStockMember
2021-01-01
2021-12-31
0000943535
us-gaap:CommonStockMember
2021-01-01
2021-12-31
0000943535
us-gaap:AdditionalPaidInCapitalMember
2021-01-01
2021-12-31
0000943535
WHEN:ForeignCurrencyTranslationAdjustmentsMember
2021-01-01
2021-12-31
0000943535
us-gaap:RetainedEarningsMember
2021-01-01
2021-12-31
0000943535
us-gaap:PreferredStockMember
2021-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
us-gaap:PreferredStockMember
2021-12-31
0000943535
us-gaap:CommonStockMember
2021-12-31
0000943535
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0000943535
WHEN:ForeignCurrencyTranslationAdjustmentsMember
2021-12-31
0000943535
us-gaap:RetainedEarningsMember
2021-12-31
0000943535
us-gaap:SubsequentEventMember
us-gaap:CommonStockMember
2022-03-21
2022-03-22
0000943535
us-gaap:SubsequentEventMember
2022-03-21
2022-03-22
0000943535
WHEN:MergerAgreementMember
WHEN:SeriesBConvertiblePreferredStockMember
WHEN:UCGINCMember
2020-04-26
2020-04-27
0000943535
WHEN:MergerAgreementMember
WHEN:SeriesBConvertiblePreferredStockMember
WHEN:UCGINCMember
2020-04-27
0000943535
WHEN:MergerAgreementMember
WHEN:SeriesBConvertiblePreferredStockMember
2020-04-26
2020-04-27
0000943535
us-gaap:CommonStockMember
srt:MaximumMember
2021-10-07
0000943535
us-gaap:CommonStockMember
srt:MinimumMember
2021-10-07
0000943535
us-gaap:CommonStockMember
WHEN:UCGINCMember
2021-12-01
2021-12-03
0000943535
WHEN:UCGINCMember
WHEN:SeriesBConvertiblePreferredStockMember
2021-12-01
2021-12-03
0000943535
2021-06-01
2021-06-21
0000943535
WHEN:ComputersAndSoftwareMember
2021-12-31
0000943535
us-gaap:FurnitureAndFixturesMember
srt:MinimumMember
2021-12-31
0000943535
us-gaap:FurnitureAndFixturesMember
srt:MaximumMember
2021-12-31
0000943535
us-gaap:ComputerEquipmentMember
2021-12-31
0000943535
us-gaap:ComputerEquipmentMember
2020-12-31
0000943535
us-gaap:FurnitureAndFixturesMember
2021-12-31
0000943535
us-gaap:FurnitureAndFixturesMember
2020-12-31
0000943535
2020-12-16
0000943535
2020-12-11
2020-12-16
0000943535
WHEN:FSCSolutionsIncMember
2020-10-26
2020-10-27
0000943535
us-gaap:SeriesAPreferredStockMember
2021-12-31
0000943535
us-gaap:SeriesAPreferredStockMember
2020-12-31
0000943535
us-gaap:SeriesAPreferredStockMember
2021-01-01
2021-12-31
0000943535
us-gaap:SeriesAPreferredStockMember
WHEN:GeorgeBaumoehlAndGayaRozensweigMember
2021-01-01
2021-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
2021-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
2020-12-31
0000943535
WHEN:MergerAgreementMember
us-gaap:CommonStockMember
WHEN:SeriesBConvertiblePreferredStockMember
2021-01-01
2021-12-31
0000943535
WHEN:MergerAgreementMember
us-gaap:CommonStockMember
WHEN:SeriesBConvertiblePreferredStockMember
2021-12-31
0000943535
us-gaap:SeriesBPreferredStockMember
WHEN:UCGINCMember
2021-12-01
2021-12-03
0000943535
us-gaap:CommonStockMember
2021-08-27
2021-08-31
0000943535
us-gaap:CommonStockMember
2021-08-31
0000943535
WHEN:ConsultantMember
2021-01-01
2021-12-31
0000943535
WHEN:ConsultantMember
2021-12-31
0000943535
WHEN:ConsultantMember
2021-08-31
0000943535
WHEN:ConsultantMember
2021-08-27
2021-08-31
0000943535
us-gaap:PrivatePlacementMember
2021-10-31
0000943535
us-gaap:PrivatePlacementMember
2021-08-01
2021-10-31
0000943535
us-gaap:PrivatePlacementMember
2021-01-01
2021-12-31
0000943535
2021-08-01
2021-10-31
0000943535
2021-11-01
2021-11-10
0000943535
us-gaap:CommonStockMember
2021-12-03
0000943535
WHEN:ConsultantAgreementMember
2021-01-01
2021-12-31
0000943535
WHEN:ConsultantAgreementMember
2021-12-31
0000943535
us-gaap:CommonStockMember
us-gaap:SubsequentEventMember
2022-11-07
2022-11-11
0000943535
us-gaap:SubsequentEventMember
us-gaap:CommonStockMember
2022-11-11
0000943535
us-gaap:SubsequentEventMember
2022-11-11
0000943535
us-gaap:CommonStockMember
2021-12-01
2021-12-03
0000943535
WHEN:BoardOfDirectorsMember
2021-06-26
2021-06-28
0000943535
WHEN:BoardOfDirectorsMember
2021-06-28
0000943535
WHEN:ExercisePriceRangeOneMember
2021-01-01
2021-12-31
0000943535
WHEN:ExercisePriceRangeOneMember
2021-12-31
0000943535
us-gaap:IsraelTaxAuthorityMember
2021-01-01
2021-12-31
0000943535
us-gaap:IsraelTaxAuthorityMember
2021-12-31
0000943535
us-gaap:GeneralAndAdministrativeExpenseMember
2021-01-01
2021-12-31
0000943535
us-gaap:GeneralAndAdministrativeExpenseMember
2020-01-01
2020-12-31
0000943535
WHEN:ShareBasedCompensationsMember
2021-01-01
2021-12-31
0000943535
WHEN:ShareBasedCompensationsMember
2020-01-01
2020-12-31
0000943535
us-gaap:ResearchAndDevelopmentExpenseMember
2021-01-01
2021-12-31
0000943535
us-gaap:ResearchAndDevelopmentExpenseMember
2020-01-01
2020-12-31
0000943535
WHEN:RozensweigMember
2020-10-03
2020-10-21
0000943535
WHEN:RozensweigMember
WHEN:GayaEmploymentAgreementMember
2020-10-03
2020-10-21
0000943535
WHEN:RozensweigMember
2020-12-01
2020-12-31
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:GioraRosenzweigMember
2022-03-22
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:GeorgeBaumoehlMember
2022-03-22
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
2022-03-21
2022-03-22
0000943535
us-gaap:SubsequentEventMember
us-gaap:CommonStockMember
WHEN:CrossMobileInvestmentAgreementMember
2022-03-21
2022-03-22
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:HenrykTomaszTromerMember
2022-02-13
2022-02-14
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:HenrykTomaszTromerMember
2022-02-14
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:HenrykTomaszTromerMember
WHEN:FirstAnniversaryMember
2022-02-13
2022-02-14
0000943535
us-gaap:SubsequentEventMember
WHEN:CrossMobileInvestmentAgreementMember
WHEN:HenrykTomaszTromerMember
WHEN:FirstAnniversaryMember
2022-02-14
0000943535
us-gaap:SubsequentEventMember
2022-01-01
2022-01-02
0000943535
us-gaap:PrivatePlacementMember
us-gaap:SubscriptionArrangementMember
us-gaap:SubsequentEventMember
2022-02-02
2022-02-28
0000943535
us-gaap:PrivatePlacementMember
us-gaap:SubscriptionArrangementMember
us-gaap:SubsequentEventMember
2022-02-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
iso4217:ILS
PART
I
Item
1. BUSINESS
Business
Overview
World
Health Energy Holdings, Inc. (“we” “us” “our” the “Company” or “WHEN”) WHEN
is a diversified energy, health, and cybersecurity technology company. On April 27, 2020, WHEN completed a reverse triangular merger
pursuant to the Agreement and Plan of Merger (the “Merger Agreement”) among the Company, R2GA, Inc., a Delaware corporation
and a wholly owned subsidiary of the Company (“Sub”), UCG, Inc., a Florida corporation (“Seller”), SG 77 Inc.,
a Delaware corporation and wholly-owned subsidiary of Seller (“SG”), and RNA Ltd., an Israeli company and a wholly owned
subsidiary of SG (“RNA”). Under the terms of the Merger Agreement, R2GA merged with and into SG, with SG remaining as the
surviving corporation and a wholly-owned subsidiary of the Company (the “Merger”). The Merger became effective as of April
29, 2020. Each of Gaya Rozensweig and George Baumeohl, directors of the Company, are also the sole shareholders and directors of UCG.
RNA
is primarily a research and development company that has been performing software design services in the field of cybersecurity. SG is
primarily engaged in the marketing and distribution of cybersecurity related products. In anticipation of the transaction contemplated
under the Merger Agreement, SG was formed and all of the cybersecurity rights and interests held by UCG, including the share ownership
of RNA, were assigned to SG.
Following
the closing, each of SG 77 and RNA became wholly-owned subsidiaries of the Company.
Recent
Developments
On
March 22, 2022 the Company, CrossMobile Sp zoo, a company formed under the laws of Poland (“CrossMobile”) and the shareholders
of CrossMobile (of which our CEO, Giora Rosenzweig, holds 40.67% and George Baumeohl, a director, holds 6.67%, of the issued preferred
share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to
purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the
Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial Investment”). The acquisition
is subject to the registration with the Polish Companies Registrar of the shares issuable to the Company in respect of the Initial Investment,
as required under local law. Upon the registration of the Company shareholdings in CrossMobnile, the closing of the Initial Investment
will be deemed to have occurred and the 10,000,000,000 Company shares of common stock will be issued to CrossMobile. In addition, for
18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, such that following
such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted
basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted shares of common
stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser agreed between
the Company and CrossMobile
We
believe that the acquisition of CrossMobile provides an opportunity in our evolution and provides us with a strong foothold in the European
market. CrossMobile is part of a limited group of licensed operators in the EU. CrossMobile
is planning to roll-out a comprehensive suite of value-added services for B2B and B2C customers in the telecom industry.
With
our involvement in CrossMobile, we expect to provide advanced cybersecurity solutions and other next-generation value-added services
to CrossMobile’s future product offerings as well the access to the EU market for our CyberSecurity products.
CyberSecurity
Business
Through
SG and RNA, we are primarily engaged in data security and analytics and provides intelligent security software and services to enterprises
and individuals worldwide The Company leverages artificial intelligence (“AI”) and machine learning to deliver innovative
solutions in the areas of cybersecurity, safety focusing on the areas of endpoint security, endpoint management and encryption.
As
the digital transformation of enterprises continues to advance, workforces are becoming more dispersed and mobile, and data and applications
are increasingly migrating to the cloud. As part of this trend, the number of connected endpoints is growing rapidly, as is their complexity
and the volume of data that they process and store. These endpoints, which include smartphones, laptops, desktops, servers, vehicles,
industrial equipment and other connected devices in the Internet of Things (“IoT”), are increasingly a target for cyber adversaries.
The COVID-19 pandemic has accelerated the decentralization of the workplace prompting many enterprises to shift to substantially remote
and mobile work models. At the same time, the threat environment has become increasingly hostile as the number of adversaries grows
and the scale and sophistication of their attacks, increasingly focused on the endpoint, continue to develop.
The
landscape of increasing vulnerability has created opportunities for secure communications platforms, endpoint cybersecurity and management
solutions, analytic tools and related services that help enterprises and individuals to secure their connected endpoints.
Our
software specializes in data protection, threat detection and response. Our Product offerings enable enterprises to protect data stored
on premises and in the cloud, confidential data belonging to customers, financial records, strategic and product plans and other intellectual
property and, on a parental or guardian level, to monitor minor children’s cyber activities.
Our
product offering, built on proprietary technology, helps enterprises protect data against cyberattacks from both internal and external
threats. Our products enable enterprises to analyze data, account activity and user behavior to detect attacks and prevents or limits
unauthorized use of sensitive information and prevents potential cyberattacks and limits others by automatically locking down data, allowing
access to those who need it. Our products efficiently sustain a secure state with automation and address additional important use cases
including data protection, data governance, compliance, data privacy, classification and threat detection and response.
Strategy
We
believe that the technology underlying our product offering is our primary competitive advantage. The strength of our solution is driven
by several proprietary technologies and methodologies that we have developed, coupled with how we have combined them into our highly
versatile platform. These advantages enable our end users to
|
● |
Prevent
trade secret and data leakage |
|
|
|
|
● |
Protect
against hackers |
|
|
|
|
● |
Minimize
loss of productivity |
|
|
|
|
● |
Detect
embezzlements and thefts |
|
|
|
|
● |
Defend
employees from harassments |
|
|
|
|
● |
Prevent
talent and client poaching |
|
|
|
|
● |
Avoid
human errors |
|
|
|
|
● |
Develop
a new level of decision-making ability based on accurate and real-time data. |
|
|
|
|
● |
Assist
parents and legal guardians in monitoring their minor children’s’ cyber online activities. |
The
Company’s go-to-market strategy focuses principally on generating revenue from software, services and licensing. The Company intends
to drive revenue growth and to achieve margins that are consistent with those of other enterprise software companies.
We
intend to sell substantially all of our products and services to distributors and resellers, which will sell to end-user customers, which
we refer to in this report as our customers.
We
believe that the COVID-19 pandemic, which continues to impact all of society has increased our long-term opportunity to help our customers
protect their data and detect threats. Companies around the world now have employees working remotely from potentially vulnerable home
networks, accessing critical on-premises data storages and infrastructure through VPNs and sharing information in cloud data stores.
We believe this trend is likely to continue in the long-term and that we are striving to capitalize on the opportunity ahead.
The
implementation of our strategies is subject to our raising significant cash resources to, of which no assurance can be provided that
we will be successful in raising the needed capital on commercially reasonable terms. As of the date of this report, we have no commitments
for any capital raise.
Product
Offerings
Our
Product offerings are comprised of two segments, one targeting for commercial enterprises (B2B) and one for the individual users (B2C).
B2B
Offerings—The B2B Cybersecurity system software development and implementation program focused on innovative solutions for
the constantly evolving cyber challenges of businesses, non-governmental organizations (NGO’s) and governmental entities.
We
recently launched OTOGRAPH, our comprehensive cybersecurity and information security system, to enable business enterprises to monitor,
analyze and prevent suspicious or harmful behavior on corporate networks and connected devices. The OTOGRAPH is designed to analyze and
prevent internal or external abuse or abnormal activity on enterprise devices, such as PCs, mobile phones, servers or any other OS-based
IOT device.
The
rapid transition to open and cloud-based remote workforce has exposed businesses and organizations across the world to higher risks of
cyber-attacks and information security breaches. To enable businesses to better protect their data and workflow, we developed a Business
Behavioral Analysis (BBA) system that enables business leaders to track all activity from any given location on a one-stop dashboard.
Developed over the past two years, OTOGRAPH provides aggregated data and a wide variety of real-time analytics such as real time monitoring
of online behavior, applications and system behavior, data breaches, internal and external connections analytics, productivity analysis
and psycholinguistic analysis. Corporations and organizations can then use the dashboard to detect suspicious human or device activities
that put their company at risk.
OTOGRAPH
was developed based on a state of the art intelligence technology combined with AI technology that processes and analyzes massive amounts
of behavioral and communication data and enables organizations to make real time accurate preventive assessments and decisions to protect
company assets and ensure operational efficiency. OTOGRAPH deploys a unique Business Behavioral Analysis (BBA) machine learning software.
Behavioral digital data is extracted from all endpoint devices that are connected to the company’s network infrastructure –
whether physically, wirelessly or remotely. The data is processed and analyzed to learn and to reveal the unique digital behavioral pattern
of the organization as a whole and of every endpoint or individual.
OTOGRAPH
then sets baselines of normal patterns for each, and constantly searches for anomalies – deviations from those expected patterns.
The anomalies are detected automatically and instantly, categorized by their type and generate push alerts which are sent to the business
leader’s dashboard and enabling him to respond to the threat.
OTOGRAPH
is continuously learning and calibrating the normal patterns and their thresholds to minimize the number of false alarms and constantly
adapt to the changing needs of organizations in real time.
B2C
Cybersecurity —The B2C Cybersecurity division targets families concerned with external cyber threats and exposures in addition
to monitoring a child’s behavioral patterns that may alert parents to potential tragedies caused by cyber bullying, pedophiles,
other predators, and depression.
SG’s
Parental System offers a comprehensive solution which is designed to enable parents wishing to observe their children’s online
and offline behavior to learn if they are accessing inappropriate websites and content and/or to protect them from a range of threats
including cyberbullying, pedophiles and other predators and identity theft.
The
Parental System line is positioned as the “ultimate parental cyber solution”. This system incorporates a range of features
enabling parents to view and manage their children’s phones. The key elements of our proprietary solutions include the following:
analysis of all incoming and outgoing written data; analysis of all incoming and outgoing audio communication; real time location tracking;
environmental surroundings analysis; and cyber activity analysis.
The
Parental System has similar features to those of the B2B yet tailored to fit the needs of parents and guardians to protect their children.
Such variations focus on online behavioral patterns whether vocally, via SMS or social media platforms. If there is a change in behavior
patterns, the product is designed to immediately send the parent or adult guardian an alert. For example, one of the identifiable indicators
before suicide is social withdrawal, something which today appears as a significant decrease in text message exchanges. The system categorizes
this decrease as a red flag. Moreover, there are certain words and phrases which increase in use prior to suicide which the system will
detect these it will put them in the red flag category.
While
analyzing voice calls based on; tone of speech, lengths of the conversation and the frequency of calls, Parental System Analytics is
capable of identifying changes in behavioral patterns and flagging these changes. For example, studies showed that with deteriorating
mental health, the frequency of calls decreases and the sentences along with the length of the conversations get shorter. Any such discrepancy
in behavior patterns will send a real time alert to the parent or legal guardian, potentially avoiding a tragedy.
Sales
and Marketing
We
license the vast majority of our products and services thru a global network of resellers and distributors that we refer to as our channel
partners. In addition, we maintain a highly trained professional sales force that is responsible for overall market development, including
the management of the relationships with our channel partners and supporting channel partners in winning customers through product demonstrations
and risk assessments. Our channel partners identify potential sales targets, maintain relationships with customers and introduce new
products to existing customers. Sales to our channel partners are generally subject to our standard, non-exclusive channel partner agreement.
Research
and Development
Our
research and development efforts are focused primarily on improving and enhancing our existing products, as well as developing new products,
features and functionality. Use of our products has expanded from data governance into areas such as data security, privacy, accessibility
and retention, and we anticipate that customers and innovation will drive functionality into additional areas. We regularly release new
versions of our products which incorporate new features and enhancements to existing ones. We conduct substantially all of our research
and development activities in Israel, and we believe this provides us with access to world-class engineering talent. In addition, we
continue to seek opportunities to extend our technological capabilities and grow our business from strategic technological tuck-in acquisitions.
Our
research and development expense was $489,210 and $497,121 in 2020 and 2021, respectively.
Intellectual
Property
We
attempt to protect our technology and the related intellectual property under trade secret laws, confidentiality procedures and contractual
provisions. No single intellectual property right is solely responsible for protecting our products. The nature and extent of legal protection
of our intellectual property rights depends on, among other things, its type and the jurisdiction in which it arises. We currently have
no issued patents.
We
rely on our unpatented proprietary technology and trade secrets. We generally enter into confidentiality agreements with our employees,
consultants, service providers, vendors and customers and generally limit internal and external access to, and distribution of, our proprietary
information and proprietary technology through certain procedural safeguards. We also rely on invention assignment agreements with our
employees, consultants and others, to assign to the Company all inventions developed by such individuals in the course of their engagement
with the Company.
In
addition to Company-owned intellectual property, we license software from third parties for integration into our solutions, including
open source software and other software available on commercially reasonable terms. It may be necessary in the future to seek or renew
licenses relating to various aspects of our products, processes and services. While we have generally been able to obtain such licenses
on commercially reasonable terms in the past, we cannot provide assurance that such third parties will maintain such software or continue
to make it available.
Competition
Our
main competition in the global parental control software market are McAfee LLC (US), Avanquest (France), Bitdefender (Romania), SaferKid
(US), Symantec Corporation (US), Webroot Inc. (US), Content Watch Holdings, Inc. (US), Verizon Communications Inc. (US), Mobicip LLC
(US), and Trend Micro Inc. (Japan). These are companies that may have been in the market longer than our company, and/or have a more
recognizable name, but our proprietary algorithms are designed to trace behavioral pattern changes in the user as opposed to the machine,
thus providing a better understanding of the user.
With
regards to the B2B product and software available to protect businesses, we believe that our B2B solution is truly unique. Our main known
competitor is Checkpoint Systems, yet, our cyber software provides unique protection by analyzing inner company behavioral patterns as
well as external, thus aiding our clients to foresee security breaches whether from an internal or external threat.
Regulatory
Environment
Foreign
and domestic laws and regulations apply to many aspects of the Company’s business.
The
Company collects and uses a wide variety of information for various purposes in its business, including to help ensure the integrity
of its services and to provide features and functionality to customers. This aspect of the Company’s business is subject to a broad
array of evolving privacy and data protection laws, including the European Union’s General Data Protection Regulation national
and state laws within the United States, including the California Privacy Rights Act. These laws impose strict operational requirements
and can provide for significant penalties for non-compliance. Elements of these evolving laws and regulations, as well as their interpretation
and enforcement, remain unclear and the Company may be required to modify its practices to comply with them in the future.
Employees
As
of April 10, 2022, we had eight (8) employees, of which six (5) are primarily engaged in research and development
and three (3) in administrative positions.
Other
Corporate Holdings
We
currently also have the following subsidiaries.
FSC
Solutions, Inc. On June 26, 2015, we entered into a Stock Purchase Agreement (the “Agreement”) with FSC and its shareholders
which included Uri Tadelis, our former Chief Executive Officer and Director and our former Directors Chaim J. Lieberman and Gal Levy.
The Agreement was effective as of July 1, 2015 which served as the closing date for the acquisition. Pursuant to the terms of the Agreement,
we acquired all of the capital stock of FSC in exchange for the issuance of 70 billion shares of our unregistered common stock with the
possibility of the issuance of an additional 130 Billion common shares upon FSC meeting certain milestones as outlined in the Agreement.
Upon completion of the acquisition of FSC, we intended to employ FSC’s software and trading platform to enter the on-line trading
industry. Subsequent to the completion of the acquisition, we determined that FSC did not have control over the trading platform and
software we expected to acquire and operate. Please refer to Item 3 of this report.
World
Health Energy, Inc. World Health Energy, Inc. owns an algae-tech business whose primary focus was the production of algae using their
proprietary GB3000 growth system. The system quickly and efficiently grows algae for the production of biofuels and food protein. We
also sought to produce and market high-quality, low-cost B100 biodiesel. Though, we believe that the Company has been successful in demonstrating
the effectiveness of the GB3000 system on a small-scale the Company has not yet been able to raise the necessary capital to implement
their technologies on a commercial scale.
Available
Information
The
public may read and copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington,
D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The
SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that
file electronically with the SEC. The address of that site is www.sec.gov. The Company’s websites are located at http://www.worldhealthenergy.com/
and http://www.whengreenenergy.com/. Information contained on, or accessible through, these websites, or any website stated in
this report, is not a part of, and is not incorporated by reference into, this report.
Item
1A. Risk Factors.
You
should consider each of the following risk factors and any other information set forth in this Form. 10-K as the other Company’s
reports filed with the SEC, including the Company’s consolidated financial statements and related notes, in evaluating the Company’s
business and prospects. The risks and uncertainties described below are not the only ones that impact the Company’s operations
and business. Additional risks and uncertainties not presently known to the Company, or that the Company currently considers immaterial,
may also impair its business or operations. If any of the following risks actually occur, the Company’s business and financial
condition, results or prospects could be harmed.
Risks
Relating to Our Business and Industry
We
will need to raise significant capital in order to realize our business plan and the failure to obtain the needed funding could lead
to our operational failure.
We
will need to raise additional working capital in order to design and develop our second-generation online security and data protection
technologies, expand our market strategy and potentially acquire complementary technologies. Without adequate funding, we also may not
be able to accelerate the development and deployment of our products, respond to competitive pressures and develop new or enhanced products.
At the present time, we have no commitments for any financing, and there can be no assurance that capital will be available to us on
commercially acceptable terms or at all. We may have difficulty obtaining additional funds as and when needed, and we may have to accept
terms that would adversely affect our stockholders. Any failure to achieve adequate funding will delay our development programs and product
launches and could lead to abandonment of one or more of our development initiatives, as well as prevent us from responding to competitive
pressures or take advantage of unanticipated acquisition opportunities.
Any
additional equity financing may be dilutive to stockholders, and debt and certain types of equity financing, if available, may involve
restrictive covenants or other provisions that would limit how we conduct our business or finance our operations.
Even
if we raise funds to address our immediate working capital requirements, we also may be required to seek additional financing in the
future to respond to increased expenses or shortfalls in anticipated revenues, accelerate product development and deployment, respond
to competitive pressures, develop new or enhanced products, or take advantage of unanticipated acquisition opportunities.
These
conditions raise substantial doubt as to our ability to continue as a going concern and may make it more difficult for us to raise additional
capital when needed. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability
of reported assets or liabilities should we be unable to continue as a going concern.
Our
independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern
in its report on our audited financial statements included in this prospectus. Our audited financial statements at December 31, 2021
and 2020 and for the years then ended were prepared assuming that we will continue as a going concern.
Primarily
as a result of our losses and limited cash balances and cash flows, the report of our independent registered public accounting firm included
elsewhere in this prospectus contains an explanatory paragraph on our financial statements stating that our ability to continue as a
going concern is highly contingent on our ability to raise capital for ongoing research and development and clinical trials as we expect
to continue to incur losses for the foreseeable future. Such an opinion could materially limit our ability to raise additional funds
through the issuance of new debt or equity securities or otherwise. There is no assurance that sufficient financing will be available
when needed to allow us to continue as a going concern. The perception that we may not be able to continue as a going concern may also
make it more difficult to operate our business due to concerns about our ability to meet our contractual obligations. We cannot provide
any assurance that we will be able to raise additional capital.
If
we are unable to secure additional capital, we may be required to curtail our clinical and research and development initiatives and take
additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.
These measures could cause significant delays in our clinical and regulatory efforts, which is critical to the realization of our business
plan. The accompanying financial statements do not include any adjustments that may be necessary should we be unable to continue as a
going concern. It is not possible for us to predict at this time the potential success of our business. The revenue and income potential
of our proposed business and operations are currently unknown. If we cannot continue as a viable entity, you may lose some or all of
your investment.
We
have a history of losses and expect to incur losses and negative operating cash flows in the future.
We
expect our operating losses to continue as we continue to expend resources to further develop and enhance our technology offering, to
complete prototypes for proof-of-concept, obtain regulatory clearances or approvals as required, expand our business development activities
and finance capabilities and conduct further research and development. We also expect to experience negative cash flow in the short-term
until licensing revenues increase from our planned acquisitions.
The
nature of the technology platforms utilized by us are complex and highly integrated, and if we fail to successfully manage releases or
integrate new updates, it could harm our revenues, operating income, and reputation.
The
technology platforms developed by us accommodate integrated applications that include our own developed technology and third-party technology,
thereby substantially increasing their functionality. By enabling such system interoperability, our communications platform both reduces
implementation and ongoing costs, and improves overall management efficiencies.
Due
to this complexity and the condensed development cycles under which we operate, we may experience errors in our software, corruption
or loss of our data, or unexpected performance issues from time to time. For example, our solutions may face interoperability difficulties
with software operating systems or programs being used by our customers, or new releases, upgrades, fixes or the integration of acquired
technologies may have unanticipated consequences on the operation and performance of our other solutions. If we encounter integration
challenges or discover errors in our solutions late in our development cycle, it may cause us to delay our launch dates. Any major integration
or interoperability issues or launch delays could have a material adverse effect on our revenues, operating income and reputation.
Security
breaches, cyberattacks or other cyber-risks of our IT and production systems could expose us to significant liability and cause our business
and reputation to suffer and harm our competitive position.
Our
corporate infrastructure stores and processes our sensitive, proprietary and other confidential information (including as related to
financial, technology, employees, marketing, sales, etc.) which is used on a daily basis in our operations. In addition to that, our
software involves transmission and processing of our customers’ confidential, proprietary and sensitive information. We have legal
and contractual obligations to protect the confidentiality and appropriate use of customer data.
High-profile
cyberattacks and security breaches have increased in recent years, with the potential for such acts heightened as a result of the number
of employees working remotely due to COVID-19. Security industry experts and government officials have warned about the risks of hackers
and cyberattacks targeting IT products and enterprise infrastructure. Because techniques used to obtain unauthorized access or to sabotage
systems change frequently and often are not recognized until launched against a specific target, we may be unable to anticipate these
techniques or to implement adequate preventative measures. As we continue to increase our client base and expand our brand, we may become
more of a target for third parties seeking to compromise our security systems and we anticipate that hacking attempts and cyberattacks
will increase in the future. We cannot give assurance that we will always be successful in preventing or repelling unauthorized access
to our systems. We also may face delays in our ability to identify or otherwise respond to any cybersecurity incident or any other breach.
Additionally, we use third-party service providers to provide some services to us that involve the storage or transmission of data, such
as SaaS, cloud computing, and internet infrastructure and bandwidth, and they face various cybersecurity threats and also may suffer
cybersecurity incidents or other security breaches. Despite our security measures, our IT and infrastructure may be vulnerable to attacks.
Threats to IT security can take a variety of forms. Individual and groups of hackers and sophisticated organizations, including state-sponsored
organizations or nation-states, continuously undertake attacks that pose threats to our customers and our IT. These actors may use a
wide variety of methods, which may include developing and deploying malicious software or exploiting vulnerabilities in hardware, software,
or other infrastructure in order to attack our products and services or gain access to our networks, using social engineering techniques
to induce our employees, users, partners, or customers to disclose passwords or other sensitive information or take other actions to
gain access to our data or our users’ or customers’ data, or acting in a coordinated manner to launch distributed denial
of service or other coordinated attacks. Inadequate account security practices may also result in unauthorized access to confidential
and/or sensitive data.
Security
risks, including, but not limited to, unauthorized use or disclosure of customer data, theft of proprietary information, theft of intellectual
property, theft of internal employee’s PII/PHI information, theft of financial data and financial reports, loss or corruption of
customer data and computer hacking attacks or other cyberattacks, could require us to expend significant capital and other resources
to alleviate the problem and to improve technologies, may impair our ability to provide services to our customers and protect the privacy
of their data, may result in product development delays, may compromise confidential or technical business information, may harm our
competitive position, may result in theft or misuse of our intellectual property or other assets and could expose us to substantial litigation
expenses and damages, indemnity and other contractual obligations, government fines and penalties, If an actual or perceived breach of
our security occurs, the market perception of the effectiveness of our security measures and our products could be harmed, we could lose
potential sales and existing customers, our ability to operate our business could be impaired, and we may incur significant liabilities,
and we could suffer harm to our reputation and competitive position, and our operating results could be negatively impact our business.
The
market opportunity for our products and services may not develop in the ways that we anticipate.
The
demand for our products and services can change quickly and in ways that we may not anticipate because the market in which we operate
is characterized by rapid, and sometimes disruptive, technological developments, evolving industry standards, frequent new product introductions
and enhancements, changes in customer requirements and a limited ability to accurately forecast future customer orders. Our operating
results may be adversely affected if the market opportunity for our products and services does not develop in the ways that we anticipate
or if other technologies become more accepted or standard in our industry or disrupt our technology platforms.
If
we are unable to maintain successful relationships with our channel partners, our business could be adversely affected.
We
rely on channel partners, such as distribution partners and resellers, to sell licenses and support and maintenance agreements for our
software and to perform some of our professional services. Our ability to achieve revenue growth in the future will depend in part on
our success in maintaining successful relationships with our channel partners.
Our
agreements with our channel partners are generally non-exclusive, meaning our channel partners may offer customers the products of several
different companies. If our channel partners do not effectively market and sell our software, choose to use greater efforts to market
and sell their own products or those of others, or fail to meet the needs of our customers, including through the provision of professional
services for our software, our ability to grow our business, sell our software and maintain our reputation may be adversely affected.
Our contracts with our channel partners generally allow them to terminate their agreements for any reason upon 30 days’ notice.
A termination of the agreement has no effect on orders already placed. The loss of a substantial number of our channel partners, our
possible inability to replace them, or the failure to recruit additional channel partners could materially and adversely affect our results
of operations. If we are unable to maintain our relationships with these channel partners, our business, results of operations, financial
condition or cash flows could be adversely affected. Finally, even if we are successful, our relationships with channel partners may
not result in greater customer usage of our products and professional services or increased revenue.
The
online security and device management industry is highly competitive, and we have a number of competitors that are larger and have greater
resources.
We
operate in an intensely competitive market which experiences rapid technological developments, changes in customer requirements and changes
in industry standards. These in addition to the frequent new product introductions and improvements offered by our competitors. Our competitive
position could weaken, and we could experience a drop-in revenue in we are not able to anticipate or react to competitive challenges
or if new or existing competitors gain market share in any of our markets. In order to successfully compete, we must maintain a successful
research and development effort to develop new product and enhance our existing products. Should we not be successful in responding to
our competitors or to changing technological and customer demands, the outcome could be a negative effect on our competitive position
and our financial results.
Another
challenge is the growing competition from network equipment and computer hardware manufacturers as well as large operating system providers.
These firms continuously develop and incorporate into their products data protection and storage and server management software that
competes at some levels with our product offerings. Our competitive position could be adversely affected to the extent that our customers
perceive the functionality incorporated into these products as replacing the need for our products.
Many
of our competitors have deeper pockets, greater technical, sales, marketing, or other resources than we do and consequently may have
the ability to influence customers to purchase their products instead of ours.
There
is uncertainty as to market acceptance of our technology and services.
The
demand for our products and services can change quickly and in ways that we may not anticipate because the market in which we operated
is characterized by rapid, and sometimes disruptive, technological development.
We
may not be able to complete or integrate successfully any potential future acquisitions, partnerships or joint ventures.
Acquisitions
can involve a number of special risks and challenges, including but not limited to:
|
● |
Complexity,
time and costs associated with the integration of acquired business operations, workforce, products and technologies into our existing
business, sales force, employee base, product lines, and technology. |
|
|
|
|
● |
Management
distraction from our existing business and other business opportunities. |
|
|
|
|
● |
Employee
termination could occur and thus inducing costs associated with the termination of those employees. |
|
|
|
|
● |
Assumption
of debt or other liabilities of the acquired business, including litigation related to the acquired business. |
|
|
|
|
● |
Increased
expenses and working capital requirements. |
|
|
|
|
● |
Dilution
of existing stockholders’ shares. |
|
|
|
|
● |
Increased
costs and efforts in connection with compliance with Section 404 of the Sarbanes-Oxley Act. |
Integrating
an acquired business can be complex, time consuming, as well as an expensive process, which can impact the effectiveness of our internal
control over financial reporting.
If
such integration is unsuccessful, we may not realize the potential benefits of an acquisition or suffer from adverse effects that we
currently cannot foresee.
Any
of the foregoing, along with other factors, could harm our ability to achieve anticipated levels of profitability from such acquired
businesses or to realize other anticipated benefits of such acquisitions. Due to the fact that acquiring high technology companies is
inherently risky, there can be no assurance that future acquisitions will be successful and shall not adversely affect our business,
financial condition or operating results.
If
we cannot keep pace with rapid developments and changes in our industry and provide new services to our clients, the use of our services
could decline, reducing our revenues.
Our
future success depends on our ability to respond to the rapidly changing needs of our customers by developing product upgrades and introducing
new products on a timely basis. Though we have and continue to incur, significant research and development expenses, the development
and introduction of a new product involves significant resources and time commitment and is therefore subject to risks including:
|
● |
Managing
the length of the development cycle for new product enhancements, which could be longer than originally anticipated. |
|
|
|
|
● |
Adapting
our products to the endlessly evolving industry standards and to our competitors’ technological developments. |
|
● |
Entering
into new markets in which we have limited experience. |
|
|
|
|
● |
Incorporating
acquired products and technologies. |
|
|
|
|
● |
Integrating
our various security and storage technologies, management solutions, and support into unified enterprise security and storage solutions. |
|
|
|
|
● |
Developing
or expanding efficient sales channels. |
In
addition, if we cannot adapt our business models to keep pace with industry trends, our revenue could be negatively impacted.
If
we are not successful in managing these risks and challenges, or if our new products, product upgrades, and services are not technologically
competitive or do not achieve market acceptance, our business and operating results could be adversely affected.
Our
cybersecurity system might be used for fraudulent, illegal or improper purposes, which could expose us to additional liability and harm
our business.
Reputation
in the cybersecurity field is an important corporate asset. An operating incident, significant cybersecurity disruption, or other adverse
event may have a negative impact on our reputation. This, in turn, could make it more difficult for us to compete successfully for new
opportunities, obtain necessary regulatory approvals, or could reduce consumer demand for our branded products.
Furthermore,
such disruptions or fraudulent use could expose us to liabilities such as lawsuits and settlements. Such liabilities could be time consuming,
costly and harmful to our business and funds.
We
may be subject to the risks of doing business internationally.
We
have significant operations outside of the U.S., including engineering, sales, customer support and production, these will be subject
to risks in addition to those faced by our domestic operations such as:
|
● |
Potential
loss of proprietary information due to misappropriation or laws that may be less protective of our intellectual property rights that
U.S. laws or may not be adequately enforced. |
|
|
|
|
● |
Governmental
control and other foreign law requirements, including labor restrictions and related laws that can impact our business operations. |
|
|
|
|
● |
Restrictions
on our ability to repatriate cash from our international subsidiaries or to exchange cash availability for use in the U.S. |
|
|
|
|
● |
Fluctuations
in currency exchange rates and economic instability such as higher interest rates in the U.S. and inflation could reduce our customers’
ability to obtain financing for software products or could make our products more expensive or could increase our costs of doing
business in certain countries. |
|
|
|
|
● |
Longer
payment cycles due to sales in foreign countries. |
|
|
|
|
● |
Difficulties
related to administering a stock plan in some foreign countries. |
|
|
|
|
● |
Delays
and costs related to developing software and providing support in various languages. |
|
|
|
|
● |
Political
unrest, war, or terrorism, particularly in areas in which we have facilities. |
Costs
of compliance with laws and regulations
We
are subject to regulatory environment changes regarding privacy and data protection and could have a material impact on our results of
operations.
The
growth and expansion of the company into a variety of new fields may potentially involve new regulatory issues/requirements such as the
EU General Data Protection Regulation (GDPR) or the New York Department of Financial Services (NYDFS) Cybersecurity Regulation. The potential
cost of compliance with or imposed by new/existing regulations and policies that are applicable to us may affect the use of our products
and services and could have a material adverse impact on our results of operations.
We
may not be able to successfully protect the intellectual property we license and may be subject to infringement claims.
We
rely on a combination of contractual rights, copyright, trademark and trade secret laws to establish and protect our proprietary technology.
We customarily require our employees and independent contractors to execute confidentiality agreements or otherwise to agree to keep
our proprietary information confidential when their relationship with us begins. Typically, our employment contracts also include clauses
requiring our employees to assign to us all of the inventions and intellectual property rights they develop in the course of their employment
and to agree not to disclose our confidential information. Nevertheless, others, including our competitors, may independently develop
similar technology to that licensed by us, duplicate our services or design around our intellectual property. Further, contractual arrangements
may not prevent unauthorized disclosure of our confidential information or ensure an adequate remedy in the event of any unauthorized
disclosure of our confidential information. Because of the limited protection and enforcement of intellectual property rights in many
foreign markets, our intellectual property rights may not be as protected as they may be in more developed markets such as the United
States. We may have to litigate to enforce or determine the scope or enforceability of our intellectual property rights (including trade
secrets and know-how), which could be expensive, could cause a diversion of resources and may not prove successful. The loss of intellectual
property protection could harm our business and ability to compete and could result in costly redesign efforts, discontinuance of certain
service offerings or other competitive harm. Additionally, we do not hold any patents for our business model or our business processes,
and we do not currently intend to obtain any such patents in Mexico, the United States or elsewhere.
We
may also be subject to costly litigation in the event our services or the technology that we license are claimed to infringe, misappropriate
or otherwise violate any third party’s intellectual property or proprietary rights. Such claims could include patent infringement,
copyright infringement, trademark infringement, trade secret misappropriation or breach of licenses. We may not be able to successfully
defend against such claims, which may result in a limitation on our ability to use the intellectual property subject to these claims
and also might require us to redesign affected services, enter into costly settlement or license agreements, pay costly damage awards,
or face a temporary or permanent injunction prohibiting us from marketing or selling certain of our services. In such circumstances,
if we cannot or do not license the infringed technology on reasonable terms or substitute similar technology from another source, our
revenue and earnings could be adversely impacted. Additionally, in recent years, non-practicing entities have been acquiring patents,
making claims of patent infringement and attempting to extract settlements from companies in our industry. Even if we believe that such
claims are without merit and successfully defend these claims, defending against such claims is time consuming and expensive and could
result in the diversion of the time and attention of our management and employees.
If
we don’t have sufficient resellers it is possible we won’t have sufficient funds for aggressive advertising campaigns thus
resulting in deficits.
We
sell our products to customers around the world through resellers. Sales through indirect channels involve a number of risks, including:
|
● |
Our
resellers are not subject to minimum sales requirements or to any obligations to market our products to their customers |
|
|
|
|
● |
Our
reseller agreements are generally nonexclusive and may be terminated at any time without cause. |
|
|
|
|
● |
It
is possible that our resellers distribute competing products and may, occasionally, place a greater emphasis on the sale of these
products due to pricing, promotions, and other terms offered by such competitors. |
We
are subject to Currency exchange rate fluctuations
Our
exposure to exchange risk mainly involves sales negotiated with customers in U.S. dollars net of expenses and possible investment or
loan repayments in this currency. The change in foreign currencies compared to the Israeli Shekel may have an impact on the profit and
loss statements for the Company.
Fluctuations
in demand for our products and services are driven by many factors, and a decrease in demand for our products could adversely affect
our financial result.
We
are subject to fluctuations in demand for our products and services due to a variety of factors, including general economic conditions,
competition, technological changes, changes in buying patterns, financial difficulties and or budget cuts of our actual and potential
customers or resellers, awareness of security threats to IT systems, and other factors. Though such factors can at times increase our
sales, yet such fluctuations could have a negative impact on our product sales. If for any reason the demand for our products declines,
our revenues and gross margin could be adversely affected.
Our
products are complex and operate in a wide variety of computer configurations, which could result in errors or product failures.
Due
to the complexity of our product, there is a chance that our products contain undetected errors, failures, or bugs, especially when products
are first introduced or when new versions are released. Our products are installed and used in large-scale computing environments, therefore
are subject to different operating systems, system management software and network configurations, all of which may cause errors or a
failure in our products. Furthermore, these may expose undetected errors, failures, or bugs in our products.
Errors,
failures, or bugs in our products could result in negative reviews and publicity, causing damage to our brand name, product returns.
These in turn could result in loss of market acceptance, loss of competitive position, or claims by customers. Finally, if an actual
or perceived breach of information integrity or availability occurs in one of our customer’s systems, regardless of whether the
breach is attributable to our products, the market perception of the effectiveness of our products could be harmed.
Solving
any of these problems could require significant expenses and other resources and could cause interruptions, delays, or cessation of our
product licensing, which could cause us to lose existing or potential customers and thus affect our operating results.
If
we are unable to attract and retain qualified employees, lose key personnel, fail to integrate replacement personnel successfully, or
fail to manage our employee base effectively, we may be unable to develop new and enhanced products and services, effectively manage
or expand our business, or increase our revenues.
Our
future success depends upon our ability to recruit and retain our key management, technical, sales, marketing, finance, and other critical
personnel. Our officers and other key personnel are employees-at-will, and we cannot assure you that we will be able to retain them as
the competition for workers with the specific skills that we require is significant. In order to attract and retain personnel in a competitive
marketplace, we believe that we must provide a competitive compensation package, including cash and equity-based compensation. The unpredictability
in our stock price may from time to time unfavorably affect our ability to recruit or retain employees. In addition, we may be unable
to obtain required stockholder approvals of future increases in the number of shares available for issuance under our equity compensation
plans, and accounting rules require us to treat the issuance of employee stock options and other forms of equity-based compensation as
compensation expense. As a result, we may decide to issue fewer equity-based incentives and may be impaired in our efforts to attract
and retain necessary personnel. If we are unable to hire and retain qualified employees, or conversely, if we fail to manage employee
performance or reduce staffing levels when required by market conditions, our business and operating results could be adversely affected.
Similarly
to every work place, from time to time, key personnel in our company may leave, which may in turn have a negative impact and result in
significant disruptions to our operations, including harming the timeliness product release, the successful implementation and completion
of company initiatives, effectiveness of our disclosure controls and procedures and our internal control over financial reports, and
the results of our operations. Furthermore, recruiting, training and successfully integrating replacement employees could be time consuming
and may result in additional disruptions to our operations, which could in turn negatively impact future revenues.
Third
parties claiming that we infringe their proprietary rights could cause us to incur significant legal expenses and prevent us from selling
our products.
There
is a possibility of future claims that we allegedly infringed the intellectual property rights of others, including claims regarding
patents, copyrights, and trademarks. In addition, former employers of our former, current, or future employees may assert claims that
such employees have improperly disclosed to us the confidential or proprietary information of these former employers. Any such claim,
with or without merit, could result in costly litigation and distract management from day-to-day operations. If we do not successfully
defend our company of such claims, we could be forced to stop selling, or redesign our products, pay monetary amounts as damages, enter
into royalty or licensing arrangements, or satisfy indemnification obligations that we have with some of our customers. We cannot assure
you that any royalty or licensing arrangements that we may seek in such circumstances will be available to us on commercially reasonable
terms or at all.
We
must comply with governmental regulations setting privacy standards.
Governmental
regulations setting environmental standards influence the design, components or operation of our products. New regulations and changes
to current regulations are always possible and, in some jurisdictions, regulations may be introduced with little or no time to bring
related products into compliance with these regulations. Our failure to comply with these regulations may prevent us from selling our
products in certain countries. In addition, these regulations may increase our cost of supplying the product by forcing us to redesign
existing products or to use more expensive designs or components. This may induce unexpected costs or operational complexities to bring
products into compliance. Such could have an adverse effect on our revenues, gross profit margins and results of operations and increase
the volatility of our financial results.
Our
business may be affected by the ongoing COVID-19 pandemic and may be significantly adversely affected as the pandemic continues or if
other events out of our control disrupt our business or that of our third party collaborators.
While
the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public
health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating
results. If the COVID-19 pandemic continues, other aspects of our may be may be adversely affected, delayed or interrupted. We currently
rely on third parties to run our business. If any such third party in our supply chain for materials is adversely impacted by effects
from the COVID-19 pandemic, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain
may be disrupted and our costs could be increased.
Our
increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact
our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible
to communication disruptions, any of which could adversely impact our business operations.
The
COVID-19 pandemic continues to evolve. The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and
subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic,
additional or modified government actions, and the actions taken to contain COVID-19 or address its impact, among others. We do not yet
know the full extent of potential delays or impacts on our business, our research programs or the global economy. We will continue to
monitor the situation closely.
In addition, our business could be significantly
adversely affected by other business disruptions to us or our third party collaborators that could seriously harm our potential future
revenue and financial condition. Our operations, and those of our collaborators, contract manufacturing organizations (CMOs) and other
contractors, consultants, and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications
failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made
disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions
could seriously harm our operations and financial condition and increase our costs and expenses.
It
may be difficult to enforce a U.S. judgment against us, our officers and directors and the foreign persons named in this registration
statement in the United States or in foreign countries, or to assert U.S. securities laws claims in foreign countries or serve process
on our officers and directors and these experts.
While
we are incorporated in the State of Delaware, currently all of our directors and executive officers are not residents of the United States,
and the foreign persons named in this Annual report on Form 10-K are located outside of the United States. The majority of our assets
are located outside the United States. Therefore, it may be difficult for an investor, or any other person or entity, to enforce a U.S.
court judgment based upon the civil liability provisions of the U.S. federal securities laws against us or any of these persons in a
U.S. or foreign court, or to effect service of process upon these persons in the United States. Additionally, it may be difficult for
an investor, or any other person or entity, to assert U.S. securities law claims in original actions instituted in foreign countries.
Foreign courts may refuse to hear a claim based on a violation of U.S. securities laws on the grounds that foreign countries are not
necessary the most appropriate forum in which to bring such a claim. Even if a foreign court agrees to hear a claim, it may determine
that foreign law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law
must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure will also be governed by foreign
countries law. There is little binding case law in foreign countries addressing the matters described above.
We
may be subject to numerous and varying privacy and security laws, and our failure to comply could result in penalties and reputational
damage.
We
are subject to laws and regulations covering data privacy and the protection of personal information, including health information. The
legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy
and data protection issues which may affect our business. In the U.S., numerou s federal and state laws and regulations, including state
security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the
collection, use, disclosure, and protection of personal information. Each of these laws is subject to varying interpretations by courts
and government agencies, creating complex compliance issues for us. If we fail to comply with applicable laws and regulations we could
be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health
information from a covered entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability
Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, or HIPAA.
Other
countries have, or are developing, laws governing the collection, use and transmission of personal information as well. The EU and other
jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, for example,
effective May 25, 2018, the GDPR replaced the prior EU Data Protection Directive (95/46) that governed the processing of personal data
in the European Union. The GDPR imposes significant obligations on controllers and processors of personal data, including, as compared
to the prior directive, higher standards for obtaining consent from individuals to process their personal data, more robust notification
requirements to individuals about the processing of their personal data, a strengthened individual data rights regime, mandatory data
breach notifications, limitations on the retention of personal data and increased requirements pertaining to health data, and strict
rules and restrictions on the transfer of personal data outside of the EU, including to the U.S. The GDPR also imposes additional obligations
on, and required contractual provisions to be included in, contracts between companies subject to the GDPR and their third-party processors
that relate to the processing of personal data. The GDPR allows EU member states to make additional laws and regulations further limiting
the processing of genetic, biometric or health data.
Any
failure to comply with the requirements of GDPR and applicable national data protection laws of EU member states, could lead to regulatory
enforcement actions and significant administrative and/or financial penalties against us (fines of up to Euro 20,000,000 or up to 4%
of the total worldwide annual turnover of the preceding financial year, whichever is higher), and could adversely affect our business,
financial condition, cash flows and results of operations.
Risks
Related to Our Securities
There
is not an active liquid trading market for the Company’s common stock.
The
Company reports under the Exchange Act and its Common Stock is eligible for quotation on the OTC Markets. However, there is no regular
active trading market in the Company’s Common Stock, and we cannot give an assurance that an active trading market will develop.
If an active market for the Company’s Common Stock develops, there is a significant risk that the Company’s stock price may
fluctuate dramatically in the future in response to any of the following factors, some of which are beyond our control:
|
● |
Variations
in our quarterly operating results; |
|
|
|
|
● |
Announcements
that our revenue or income are below analysts’ expectations; |
|
● |
General
economic slowdowns; |
|
|
|
|
● |
Sales
of large blocks of the Company’s common stock; and |
|
|
|
|
● |
Announcements
by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments. |
Directors,
executive officers, principal stockholders and affiliated entities own a significant percentage of our capital stock, and they may make
decisions that our stockholders do not consider to be in their best interests.
As
of the date of this current report on Form 10-K, our directors, executive officers, principal stockholders and affiliated entities beneficially
own, in the aggregate, approximately 90% of our outstanding voting securities. Additionally, Ms. Gaya
Rozensweig, one of our directors, holds Series A preferred Stock which allows her to vote with holders of the Common Stock on an as converted
basis giving her effective control of any vote.
This
concentration of ownership may have the effect of delaying or preventing a change in control of our company that may be favored by other
stockholders. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market
prices. This concentration of ownership and influence in management and board decision-making could also harm the price of our capital
stock by, among other things, discouraging a potential acquirer from seeking to acquire shares of our capital stock (whether by making
a tender offer or otherwise) or otherwise attempting to obtain control of our company.
The
market price of our common stock may be volatile and such volatility could cause you to lose some or all of your investment.
The
market price of our common stock can fluctuate, and as a result you could lose the value of your investment. The market price of our
common stock may be affected by a number of factors, including:
|
● |
Announcements
of quarterly operating results and revenue and earnings predictions we made and failed to meet or be consistent with such earlier
projections or the expectations of our investors. |
|
|
|
|
● |
Rumors,
announcements, or press articles regarding our competitors’ operations, management, organization, financial condition, or financial
statements. |
|
|
|
|
● |
Changes
in revenue and earnings estimates by us or our investors. |
|
|
|
|
● |
Announcements
of planned acquisitions or dispositions by us or by our competitors. |
|
|
|
|
● |
Announcement
of a new or planned product to be released either by us, our competitors or our customers. |
|
● |
Acquiring
or losing a significant customer. |
|
|
|
|
● |
Inquiries
by the SEC, NASDAQ, law enforcement or other regulatory bodies. |
|
|
|
|
● |
Acts
of terrorism, the threat of war, and other crises or emergency situations. |
|
|
|
|
● |
Economic
slowdowns or the perception of an oncoming economic slowdown in any of the major markets in which we operate. |
Because
we became public by means of a reverse acquisition, we may not be able to attract the attention of brokerage firms.
We
may be subject to additional risks because we became public through a reverse acquisition. Securities analysts of brokerage firms may
not provide coverage of our company since there is little incentive for brokerage firms to recommend the purchase of our common stock.
No assurance can be given that brokerage firms will want to conduct secondary offerings on our behalf in the future.
Our
Board of Directors may issue and fix the terms of shares of our Preferred Stock without stockholder approval, which could adversely affect
the voting power of holders of our Common Stock or any change in control of our Company.
Our
Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of “blank check” preferred stock, with a
$0.0007 par value per share (the “Preferred Stock”), with such designation rights and preferences as may be determined from
time to time by the Board of Directors. Our Board of Directors is empowered, without shareholder approval, to issue shares of Preferred
Stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of
the holders of our Common Stock. In the event of such issuances, the Preferred Stock could be used, under certain circumstances, as a
method of discouraging, delaying or preventing a change in control of our Company.
Our
board of directors has significant control over us and we have yet to establish committees comprised of independent directors.
We
only have two directors. Because of such limited number of directors, each of our board members has significant control over all corporate
issues. Our directors were also the former owners of RNA.
We
have not yet established board committees comprised of independent members. Our directors perform these functions, despite there not
being independent directors. Thus, there is potential conflict in that our directors are also engaged in management and participated
in decisions concerning management compensation and audit issues. While we intend to rectify this situation by expanding the board of
directors and forming independent audit and compensation committees, there is no assurance that we will be able to do so.
If
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or detect
fraud. Consequently, investors could lose confidence in our financial reporting and this may decrease the trading price of our stock.
We
must maintain effective internal controls to provide reliable financial reports and to detect and prevent fraud. If we cannot provide
reliable financial reports or prevent fraud, we may not be able to manage our business as effectively as would be possible with an effective
control system in place. We have not performed an in-depth analysis to determine if historical undiscovered failures of internal controls
exist, and may in the future discover areas of our internal control that need improvement.
We
have been assessing our internal controls to identify areas that need improvement. We are in the process of implementing changes to internal
controls but have not yet completed implementing these changes. Failure to implement these changes to our internal controls or any others
that it identifies as necessary to maintain an effective system of internal controls could harm our operating results and cause investors
to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on the trading price
of our common stock.
We
do not expect to pay dividends and investors should not buy our Common Stock expecting to receive dividends.
We
do not anticipate that we will declare or pay any dividends in the foreseeable future. Consequently, you will only realize an economic
gain on your investment in our Common Stock if the price appreciates. You should not purchase our Common Stock expecting to receive cash
dividends. Since we do not pay dividends, and if we are not successful in establishing an orderly trading market for our shares, then
you may not have any manner to liquidate or receive any payment on your investment. Therefore, failure to pay dividends may result in
you not seeing any return on your investment even if our business operations are successful. In addition, because we do not pay dividends,
we may have trouble raising additional funds which could affect our ability to expand our business operations.
We
are likely to raise additional funds, finance acquisitions or develop strategic relationships by issuing capital stock.
We
have financed our operations, and we expect to continue to finance our operations, acquisitions and develop strategic relationships,
by issuing equity or convertible debt securities, which could significantly reduce the percentage ownership of our existing stockholders.
Furthermore, any newly issued securities could have rights, preferences and privileges senior to those of our existing Common Stock.
Moreover, any issuances of equity securities made by us may be at or below the prevailing market price of our Common Stock and in any
event may have a dilutive impact on your ownership interest, which could cause the market price of our Common Stock to decline.
We
may also raise additional funds through the incurrence of debt, and the holders of any debt we may issue would have rights superior to
your rights in the event we are not successful and are forced to seek the protection of the bankruptcy laws.
Item
1B. Unresolved Staff Comments.
None.
Item
2. Properties.
Since
May 8, 2018, the Company’s executive offices were, and continue to be at 1825 NW Corporate Blvd., Suite 110, Boca Raton, FL 3343.
The Company pays $99 per month to lease this office space.
Our
subsidiary RNA Ltd. currently has a corporate office located in, Herzliya, Israel. The office comprises approximately 247 square meters.
The lease term for this office is from December 2020 through December 2024 and our monthly renal payment is approximately $4,700.
We
believe that our facilities are generally in good condition and suitable to carry on our business. We also believe that, if required,
suitable alternative or additional space will be available to us on commercially reasonable terms.
Item
3. Legal Proceedings.
On
October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal
Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The suit relates to the Stock Purchase
Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and
outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner
of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion
of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate.
The Suit sought declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the FSC transaction
that are still outstanding.
A
hearing was set for January 6, 2021 whereupon mediation was ordered. Mediation meetings were held but no resolution was reached.
The Florida lawsuit is currently pending.
On
or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the
shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained
the services of Delaware counsel and has moved to dismiss or stay the 2022 Lawsuit in favor of the previously filed Florida lawsuit,
which involves the same parties and same issues. The Company’s motion is currently pending in the Delaware Court of Chancery.
From
time to time we may become involved in various legal proceedings that arise in the ordinary course of business, including actions related
to our intellectual property. Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not
aware of any such legal proceedings that arise in the ordinary course of business, including actions related to our intellectual property.
Although the outcomes of these legal proceedings cannot be predicted with certainty, we are currently not aware of any such legal proceedings
or claims that we believe, either individually or in the aggregate, will have a material adverse effect on our business, financial condition,
or results of operations.
Item
4. MINE SAFETY DISCLOSURES
Not
applicable
PART
III
Item
10. Directors, Executive Officers, and Corporate Governance.
Set
forth below are the names, ages, position with the Company and business experiences of the executive officers and directors of the Company.
Name |
|
Age |
|
Position(s)
with Company |
|
|
|
|
|
Giora
Rozensweig |
|
49 |
|
Interim
Chief Executive Officer |
Maj (Ret) Danny Yatom |
|
77 |
|
President |
Gaya
Rozensweig |
|
41 |
|
Director |
George
Baumoehl |
|
56 |
|
Director |
Our
directors are appointed for one-year terms to hold office until the next annual general meeting of the holders of our Common Stock or
until removed from office in accordance with our by-laws. Our officers are appointed by our board of directors and hold office until
removed by our board of directors.
Giora
Rozensweig. Mr. Rozensweig, age 49, holds degrees in software development, application DBA and IT, which he received from Kedem
College in 1994. Mr. Rozensweig has twenty years of experience in the industry and has worked with the Israeli Government, Hewlett Packard,
IBM, and Checkpoint. He is also the co-founder of RNA Technology Ltd. where he has served as Chief Executive Officer since 2015. Previously
Mr. Rozensweig served as Chief Executive Officer of Tomagi, Ltd. from 2008 until 2015.
Maj.
Gen. (Ret.) Yatom, age 77 has over 40 years of experience in top intelligence and
security leadership roles, including as the Director of Mossad, the national intelligence and special operations agency of Israel and
one of the world’s leading intelligence secret and operations agencies. From 1999 to 2001, he served as Chief of Staff for
Security and Policy to Prime Minister Ehud Barak. He also served in various positions in the Israeli security forces and government,
including head of the Israeli Defense Forces’ Planning Directorate, commander of the Central Command, and military secretary to
defense ministers Moshe Arens and Yitzhak Rabin and prime ministers Yitzhak Rabin and Shimon Peres. He holds Bachelor of Science degree
in Physics, Mathematics and Computer Science from the Hebrew University in Jerusalem and Master of Arts degree in the Middle Eastern
studies from Tel Aviv University
Gaya
Rozensweig. Mrs. Rozensweig, age 40, holds a Degree in Business Management & Information Systems, which she received from
the College of Management, Jerusalem in 2003. Mrs. Rozensweig is a co-founder of RNA Technology Ltd. and has headed the sales and marketing
of a startup with a 27-person team that worked with government offices, banks, insurance companies. Mrs. Rozensweig has served as Chief
Financial Officer of RNA Technology, Ltd. since 2015. Previously she served as Chief Financial Officer at Tomagi Ltd. from 2008 until
2015.
George
Baumoehl. Mr. Baumoehl, age 56, George holds a MSc. Degree in Architecture and Construction Economics from University College
London which he received in 1993. Mr. Baumoehl has a background in a real estate investment and development and brings a professional
outside look into our Company. He has been the Chief Executive Officer of Spectrum Real Estate Management GmbH & Co. KG since 2006.
Giora
Rozensweig is the spouse of Gaya Rozensweig. Other than the foregoing, there is no family relationship between the Interim Chief Executive
Officer, the directors and any director or executive officer of the Company or any person nominated or chosen to become a director or
executive officer of the Company.
Involvement
in Certain Legal Proceedings
None
of our directors, executive officers, significant employees or control persons has been involved in any legal proceeding listed in Item
401(f) of Regulation S-K in the past 10 years.
Corporate
Governance
Our
board of directors has not established any committees, including an audit committee, a compensation committee or a nominating committee,
or any committee performing a similar function. The functions of those committees are being undertaken by our board. Because we do not
have any independent directors, our board believes that the establishment of committees of our board would not provide any benefits to
our Company and could be considered more form than substance.
We
do not have a policy regarding the consideration of any director candidates that may be recommended by our stockholders, including the
minimum qualifications for director candidates, nor has our officers and directors established a process for identifying and evaluating
director nominees. We have not adopted a policy regarding the handling of any potential recommendation of director candidates by our
stockholders, including the procedures to be followed. Our officers and directors have not considered or adopted any of these policies
as we have never received a recommendation from any stockholder for any candidate to serve on our board of directors.
Given
our relative size and lack of directors’ and officers’ insurance coverage, we do not anticipate that any of our stockholders
will make such a recommendation in the near future. While there have been no nominations of additional directors proposed, in the event
such a proposal is made, all current members of our board will participate in the consideration of director nominees.
As
with most small, early stage companies until such time as we further develop our business, achieve a stronger revenue base and have sufficient
working capital to purchase directors’ and officers’ insurance, we do not have any immediate prospects to attract independent
directors. When we are able to expand our board to include one or more independent directors, we intend to establish an audit committee
of our board of directors. It is our intention that one or more of these independent directors will also qualify as an audit committee
financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our board members be independent
and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our board of directors
include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our
board.
Code
of Ethics
We
adopted a Code of Ethics and Business Conduct that applies to our principal executive officer, principal financial officer, principal
accounting officer or controller, or persons performing similar functions. We undertake to provide to any person without charge, upon
request, a copy of our Code of Ethics and Business Conduct.
Role
of Board in Risk Oversight Process
Management
is responsible for the day-to-day management of risk and for identifying our risk exposures and communicating such exposures to our board.
Our board is responsible for designing, implementing and overseeing our risk management processes. The board does not have a standing
risk management committee, but administers this function directly through the board as a whole. The entire board considers strategic
risks and opportunities and receives reports from its officers regarding risk oversight in their areas of responsibility as necessary.
We believe our board’s leadership structure facilitates the division of risk management oversight responsibilities and enhances
the board’s efficiency in fulfilling its oversight function with respect to different areas of our business risks and our risk
mitigation practices.
Director
Compensation
Historically,
our non-employee directors have not received compensation for their service outside the compensation set forth in the Summary Compensation
Table below, but we may compensate our directors for their service in the future. We reimburse our non-employee directors for reasonable
travel expenses incurred in attending board and committee meetings. We also intend to allow our non-employee directors to participate
in any equity compensation plans that we adopt in the future.
Conflicts
of Interest
None
of our officers will devote more than a portion of his or her time to our affairs. There will be occasions when the time requirements
of our business conflict with the demands of the officers other business and investment activities. Such conflicts may require that we
attempt to employ additional personnel. There is no assurance that the services of such persons will be available or that they can be
obtained upon terms favorable to us.
Our
officers, directors and principal shareholders may actively negotiate for the purchase of a portion of their common stock as a condition
to, or in connection with, a proposed merger or acquisition transaction, if any. In the event that such a transaction occurs, it is anticipated
that a substantial premium may be paid by the purchaser in conjunction with any sale of shares by our officers, directors and principal
shareholders made as a condition to, or in connection with, a proposed merger or acquisition transaction. The fact that a substantial
premium may be paid to members of our management to acquire their shares creates a conflict of interest for them and may compromise their
state law fiduciary duties to our other shareholders. In making any such sale, members of Company management may consider their own personal
pecuniary benefit rather than the best interests of the Company and the Company’s other shareholders, and the other shareholders
are not expected to be afforded the opportunity to approve or consent to any particular buy-out transaction involving shares held by
members of Company management.
It
is not currently anticipated that any salary, consulting fee, or finder’s fee shall be paid to any of our directors or executive
officers, or to any other affiliate of us except as described under Executive Compensation below. Although management has no current
plans to cause us to do so, it is possible that we may enter into an agreement with an acquisition candidate requiring the sale of all
or a portion of the Common Stock held by our current stockholders to the acquisition candidate or principals thereof, or to other individuals
or business entities, or requiring some other form of payment to our current stockholders, or requiring the future employment of specified
officers and payment of salaries to them. It is more likely than not that any sale of securities by our current stockholders to an acquisition
candidate would be at a price substantially higher than that originally paid by such stockholders. Any payment to current stockholders
in the context of an acquisition involving us would be determined entirely by the largely unforeseeable terms of a future agreement with
an unidentified business entity.
Section
16(a) Beneficial Ownership Reporting Compliance
Section
16(a) of the Exchange Act requires our executive officers and directors, and persons who beneficially own more than 10% of a registered
class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual
reports concerning their ownership of our common shares and other equity securities, on Forms 3, 4 and 5 respectively. Executive officers,
directors and greater than 10% shareholders are required by the SEC regulations to furnish us with copies of all Section 16(a) reports
they file. Based on our review of the copies of such forms received by us, and to the best of our knowledge, all executive officers,
directors and persons holding greater than 10% of our issued and outstanding stock have not filed the required reports in a timely manner
during the fiscal year ended December 31, 2021.
Item
11. Executive Compensation.
The
following table sets forth certain compensation information for: (i) our principal executive officer or other individual serving in a
similar capacity during our fiscal year ended December 31, 2021, (ii) our two most highly compensated executive officers other than our
principal executive officers who were serving as executive officers at December 31, 2021 whose compensation exceed $100,000 and (iii)
up to two additional individuals for whom disclosure would have been required but for the fact that the individual was not serving as
an executive officer at December 31, 2021. Compensation information is shown for the fiscal years ended December 31, 2021 and 2020:
SUMMARY
COMPENSATION TABLE
Name
and Principal Position | |
Year | | |
Salary | | |
Bonus | | |
Stock
Awards | | |
Option
Awards (1) | | |
Non-Equity
Incentive Plan Compensation | | |
Non-Qualified
Deferred Compensation Earnings | | |
All
Other Compensation | | |
Total | |
Giora
Rozensweig | |
| 2021 | | |
| 139,086 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 139,086 | |
| |
| 2020 | | |
| 93,255 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 93,255 | |
Gaya
Rozensweig | |
| 2021 | | |
| 83,025 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 83,025 | |
| |
| 2020 | | |
| 74,524 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 74,524 | |
Danny
Yatom | |
| 2021 | | |
| - | | |
| - | | |
| - | | |
| 1,838,930 | 2 | |
| - | | |
| - | | |
| - | | |
| 1,838,930 | |
| |
| 2020 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
1. In accordance with
SEC rules, the amounts in this column reflect the fair value on the grant date of the option awards granted to the named executive, calculated
in accordance with ASC Topic 718. Stock options were valued using the Black-Scholes model. The grant-date fair value does not necessarily
reflect the value of shares which may be received in the future with respect to these awards. The grant-date fair value of the stock
options in this column is a non-cash expense for us that reflects the fair value of the stock options on the grant date and therefore
does not affect our cash balance. The fair value of the stock options will likely vary from the actual value the holder receives because
the actual value depends on the number of options exercised and the market price of our Common Stock on the date of exercise. For a discussion
of the assumptions made in the valuation of the stock options, see Note 9 to the financial reports attached to this Annual Report.
2.
Represents compensation expense recorded by the Company in respect of the
options for 6,000,000,000 shares granted in June 2021.
Employment Agreements with Executive Officers
On
October 21, 2020, RNA Ltd., the Company’s subsidiary, and Giora Rozensweig, the Company’s interim Chief Executive Officer,
entered into an employment agreement providing for the employment (the “Giora Employment Agreement”) of Mr. Giora Rozensweig
as RNA’s Chief Executive Officer, with retroactive application to July 1, 2020. Under the Giora Employment Agreement, Mr. Rozensweig
is paid an annual gross salary of the current New Israeli Shekel equivalent of $133,500, payable monthly. Under the Giora Rozensweig
Employment Agreement he also receives the following: (i) Manager’s Insurance under Israeli law for the benefit of Mr. Rosenzweig
pursuant to which RNA contributes amounts equal to (a) 8-1/3 percent (and Mr. Rosenzweig contributes an additional 5%) of each monthly
salary payment, and (b) 6.5% of Mr. Rosenzweig’s salary (with Mr. Rosenzweig contributing an additional 6%) to a pension fund,
a form of deferred compensation program established under Israeli law. The Giora Employment Agreement also contains certain provisions
for termination by RNA, which may result in a severance payment equal to twenty four months of base salary then in effect.
1On
October 21, 2020, RNA Ltd., the Company’s subsidiary, and Gaya Rozensweig entered into an employment agreement providing for the
employment (the “Gaya Employment Agreement”) of Ms. Gaya Rozensweig as RNA’s controller, with retroactive application
to July 1, 2020. Under the Gaya Employment Agreement, Ms. Rozensweig is paid an annual gross salary of the current New Israeli Shekel
equivalent of $93,500, payable monthly. Under the Rosenzweig Employment Agreement, she also receives the following: (i) Manager’s
Insurance under Israeli law for the benefit of Ms. Rosenzweig pursuant to which RNA contributes amounts equal to (a) 8-1/3 percent (and
Ms. Rosenzweig contributes an additional 5%) of each monthly salary payment, and (b) 6.5% of Ms. Rosenzweig’s salary (with Ms.
Rosenzweig contributing an additional 6%) to a pension fund, a form of deferred compensation program established under Israeli law. The
Gaya Employment Agreement also contains certain provisions for termination by RNA, which may result in a severance payment equal to twenty
four months of base salary then in effect.
Termination
of Employment and Change of Control Arrangement
Under
each of the Giora Employment Agreement and the Gaya Employment Agreement, in the event that the Company terminates the agreement for
reasons other than casue, then the employee is entited to two years of salary payments.
OUTSTANDING
EQUITY AWARDS AT DECEMBER 31, 2021
The following table sets
forth information concerning equity awards held by each of our Named Executive Officers as of December 31, 2021.
Name | |
Number of Securities
Underlying Options (#) Exercisable | | |
Number of Securities
Underlying Options (#) Unexercisable | | |
Option
Exercise Price ($) | | |
Option Expiration Date | |
Number of Securities
Underlying RSUs (#) Unvested | |
Danny Yatom | |
| - | | |
| 6,000,000,000 | | |
$ | 0.0001 | | |
6/26/31 | |
| -- | |
There
were no outstanding equity awards at December 31, 2021 to our named executive officers.
Compensation
of Directors
We
have no standard arrangements for compensating our board of directors for their attendance at meetings of the Board of Directors.
Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
The
following table sets forth certain information concerning the number of shares of our common and preferred stock owned beneficially
as of April 10, 2022 by: (i) our directors and executive officer; and (ii) each person or group of persons known by us to
beneficially own more than 5% of our outstanding shares of common stock. Unless otherwise indicated, the shareholders listed below
possess sole voting and investment power with respect to the shares they own.
Under
securities laws, a person is considered to be the beneficial owner of securities owned by him (or certain persons whose ownership is
attributed to him) or securities that can be acquired by him within 60 days, including upon the exercise of options, warrants or convertible
securities. The Company determines a beneficial owner’s percentage ownership by assuming that options, warrants and convertible
securities that are held by the beneficial owner, but not those held by any other person, and which are exercisable within 60 days, have
been exercised or converted.
The
Company believes that all persons named in the table have sole voting and investment power with respect to all shares of Common Stock
shown as being owned by them. Unless otherwise indicated, the addr ess of each beneficial owner in the table set forth below is care
of World Health Energy Holdings, Inc. at 1825 NW Corporate Blvd. Suite 110, Boca Raton, FL 3343.
Name of Beneficial Owner | |
COMMON STOCK | | |
% of class (Common Stock) (1) | | |
SERIES A PREFERRED STOCK (4) | | |
% of class (Series A Preferred) | | |
| | |
| |
Officers and Directors | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Giora Rozensweig, Interim Chief Executive Officer | |
| — | (2) | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | |
Gaya Rozensweig, Director | |
| 27,383,333,333 | (3) | |
| 5.61 | % | |
| 2,500,000 | | |
| 50 | % | |
| — | | |
| — | |
George Baumeohl. Director | |
| 17,683,333,334 | (3) | |
| 3.62 | % | |
| 2,500,000 | | |
| 50 | % | |
| — | | |
| — | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
5% or More Shareholders | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
UCG, Inc. (3) | |
| 387,000,000,000 | | |
| 79.22 | % | |
| | | |
| | | |
| | | |
| | |
Total Held by Officers and Directors of Each Class | |
| 45,066,666,666 | | |
| 88.45 | % | |
| 5,000,000 | | |
| 100 | % | |
| — | | |
| — | |
|
1. |
Based
on 489,839,407,996 shares of Common Stock outstanding as of April 10, 2022. |
|
2. |
Gaya
Rozensweig is the spouse of Giora Rozensweig. While the shares of Common Stock are held as of record by Gaya Rozensweig, both persons
may be deemed to control the voting and disposition of these shares. |
|
|
|
|
3. |
The
sole shareholders and directors of UCG, Inc. are Gaya Rozensweig and George Baumeohl and, as such, they may be deemed to beneficially
own these shares. The address of UCG Inc. is 1825 NW Corporate Blvd. Suite 110, Boca Raton, Florida 33431. |
|
|
|
|
4. |
The
Series A Preferred Stock were issued in August 2019 to each of Gaya Rozensweig and George Baumeohl. The Series A Preferred Stock
is authorized to vote with the Common Stock in all stockholder meetings that the Common Stock may vote and each share has voting
power equal to 10,000 votes per share. |
Item
13. Certain Relationships and Related Transactions and Director Independence.
On
December 31, 2020, the Company, UCG, RNA, Gaya Rozensweig, Giora Rozensweig and George Baumoehl entered into a Set-Off Agreement pursuant
to which the parties set-off a debit balance of $250,609 owed by Gaya Rozensweig and Giora Rozensweig to RNA Ltd. against the credit
balance of UCG, Inc.
On
December 31, 2020, Giora Rozensweig and our subsidiary SG entered into an Irrevocable License and Royalty Agreement pursuant to which
Mr. Rozensweig granted to the WHEN group an irrevocable worldwide license certain technologies and the related intelelctual rights. In
consideration of such license, Mr. Rozensweig is entitled to 1.5% of annual gross revenues, payable on a quarterly basis. The payments
are to be made at such time as the WHEN Group’s revenues exceed on an aggregate basis $120,000.
On
March 22, 2022 the Company, CrossMobile S.P.Zooand the shareholders of CrossMobile (of which Mr. Giora Rosenzweig, holds 40.67% and Mr.
George Baumeohl holds 6.67%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”)
pursuant to which the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in
consideration of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock (the “Initial
Investment”). The acquisition is subject to the registration with the Polish Companies Registrar of the shares issuable to the
Company in respect of the Initial Investment, as required under local law. Upon the registration of the Company shareholdings in CrossMobnile,
the closing of the Initial Investment will be deemed to have occurred and the 10,000,000,000 Company shares of common stock will be issued
to CrossMobile.
Item
14. Principal Accounting Fees and Services.
The
following table shows the fees that were billed for the audit and other services.In May 2020 Halperin Ilanit CPA was appointed as
the Company’s auditors. The amounts for the years ended December 31, 2021 and 2020 reflects amounts paid to Halperin
Ilanit CPA.
| |
2021 | | |
2020 | |
Audit Fees | |
$ | 27,500 | | |
$ | 27,500 | |
Audit-Related Fees | |
| — | | |
| — | |
Tax Fees | |
| — | | |
| — | |
All Other Fees | |
| — | | |
| — | |
Total | |
$ | 27,500 | | |
| 27,500 | |
Audit
Fees — This category includes the audit of our annual financial statements, review of financial statements included in our
Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection
with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or as
a result of, the audit or the review of interim financial statements.
Audit-Related
Fees — This category consists of assurance and related services by the independent registered public accounting firm that are
reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit
Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the SEC and
other accounting consulting.
Tax
Fees — This category consists of professional services rendered by our independent registered public accounting firm for tax
compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.
All
Other Fees — This category consists of fees for other miscellaneous items.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 - GENERAL
World
Health Energy Holdings, Inc., (the “Company” or “WHEN”), was formed on May 21, 1986, under the laws of the State
of Delaware. The Company has invested in and abandoned a variety of software programs that it strove to commercialize.
UCG,
INC. (the “UCG”) was incorporated on September 13, 2017, under the laws of the State of Florida. The Company wholly-owns
the issued and outstanding shares of RNA Ltd. (Hereinafter: “RNA”).
RNA
is primarily a research and development company that has been performing software design work for UCG in the field of cybersecurity under
the terms of development agreement between UCG and RNA. UCG is primarily engaged in the marketing and distribution of cybersecurity related
products.
In
anticipation of the transaction contemplated under the Merger Agreement, SG 77 Inc. a Delaware Corporation and a wholly-owned subsidiary
of UCG (“SG”), was incorporated on April 16, 2020 and all of the cybersecurity rights and interests held by UCG, including
the share ownership of RNA, were assigned to SG.
On
March 22, 2022 the Company, CrossMobile S.P.Zoo (“CrossMobile”) and the shareholders of CrossMobile (of which several are
related parties in the Company), entered into an Investment Agreement (the “Agreement”) pursuant to which,
the Company is to purchase 26% of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration
of the issuance by the Company to CrossMobile of 10,000,000,000 restricted shares of Company common stock. In addition, for 18 months
following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile, such that following such
additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital on a fully diluted basis.
(see Note 15 for additional information).
On
April 27, 2020, the Company completed a reverse triangular merger pursuant to the Agreement and Plan of Merger (the “Merger Agreement”)
among WHEN, R2GA, Inc., a Delaware corporation and a wholly owned subsidiary of WHEN (“Sub”), UCG, SG, and RNA. Under the
terms of the Merger Agreement, R2GA merged with SG, with SG remaining as the surviving corporation and a wholly-owned subsidiary of the
WHEN (the “Merger”). The Merger was effective as of April 27, 2020 whereby SG became a direct and wholly owned subsidiary
of WHEN and RNA indirect wholly owned subsidiary of WHEN. Each of Gaya Rozensweig and George Baumeohl, directors of WHEN, are also the
sole shareholders and directors of WHEN.
As
consideration for the Merger, WHEN issued to UCG 3,870,000 Series B Convertible Preferred Stock, par value $0.0007 per share, of WHEN
(the “Series B Preferred Shares”). Each share of the Series B Preferred Shares will automatically convert into 100,000 shares
of WHEN’s common stock, par value $0.0007 (the “Common Stock”), for an aggregate amount of 387,000,000,000 shares of
WHEN’s Common Stock, upon the filing with the Secretary of State of Delaware of an amendment to WHEN’s certificate of incorporation
increasing the number of authorized shares of Common Stock that the Company is authorized to issue from time to time.
On
October 7,2021, and following the Shareholders’ meeting approval, the Company increase its authorized shares to 750,000,000,000
(from 110,000,000,000
shares) and changed the par value of the common
stock to $0.00001
per share (from $0.0007)
(see Note 8).
Following
the effectiveness of the Amendment referred to above, on December 3, 2021, the Company issued 387,000,000,000
shares of the Company’s common stock to
UCG, Inc. upon the automatic conversion of all 3,870,000
outstanding shares of the Company’s Series
B Preferred Shares issued in April 2020 in connection with the acquisition of RNA, Ltd. From UCG, Inc.
The
Company, collectively with SG, Sub and RNA are hereunder referred to as the “Group”.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – GENERAL (continue)
The
transaction was accounted for as a reverse asset acquisition in accordance with generally accepted accounting principles in the United
States of America (“GAAP”). Under this method of accounting, SG was deemed to be the accounting acquirer for financial reporting
purposes. This determination was primarily based on the facts that, immediately following the Merger: (i) SG’s stockholders owned
a substantial majority of the voting rights in the combined company, (ii) SG designated a majority of the members of the initial board
of directors of the combined company, and (iii) SG’s senior management holds all key positions in the senior management of the
combined company. As a result of the Recapitalization Transaction, the shareholders of SG received the largest ownership interest in
the Company, and SG was determined to be the “accounting acquirer” in the Recapitalization Transaction.
As
a result, the historical financial statements of the Company were replaced with the historical financial statements of SG. The number
of shares prior to the reverse capitalization have been retroactively adjusted based on the equivalent number of shares received by the
accounting acquirer in the Recapitalization Transaction.
| C. | Board
and Shareholder Authority for Reverse Stock Split |
On
June 21, 2021, Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation (the “Reverse
Stock Split Certificate of Amendment”) in order to effect a reverse stock split of the Company’s common stock pursuant to
a range of between 1,000-to-1 and 15,000-to-1 (the “Reverse Stock Split”), when and as determined by the Company’s
Board of Directors. Pursuant to the Reverse Stock Split, each one thousand or fifteen thousand shares of common stock, or any other figure
within that range, as shall be determined by the Board of Directors at a later time, will be automatically converted, without any further
action by the stockholders, into one share of common stock. The Reverse Stock Split Certificate of Amendment will be effective upon receipt
of approval from the Financial Industry Regulatory Authority (“FINRA”) for the Reverse Stock Split and the filing with the
Secretary of the State of Delaware. As of the date of this report, the Board of Directors has not determined any particular range for
the Reverse Stock Split and no application has been presented to FINRA.
| D. | Going
concern uncertainty |
Since
inception, the Group has devoted substantially all its efforts to research and development. The Group is still in its development stage
and the extent of the Group’s future operating losses and the timing of becoming profitable, if ever, are uncertain. As of December
31, 2021, the Group had $46,022
of cash and cash equivalents, accumulated deficit of $6,093,450,
working capital of $547,972
and net losses of $4,596,813
during the year ended December 31, 2021.
The
Group will need to secure additional capital in the future in order to meet its anticipated liquidity needs primarily through the sale
of additional Common Stock or other equity securities and/or debt financing. Funds from these sources may not be available to the Group
on acceptable terms, if at all, and the Group cannot give assurance that it will be successful in securing such additional capital (see
Note 8 in respect to subscription agreements signed during 2021).
These
conditions raise substantial doubt about the Company’s ability to continue to operate as a “going concern.” The Company’s
ability to continue operating as a going concern is dependent on several factors, among them is the ability to raise sufficient additional
funding.
The
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
1 – GENERAL (continue)
| E. | The
COVID-19 pandemic continues to create business and economic uncertainty and volatility in
the global markets. Many countries around the world are experiencing further outbreaks of
the pandemic, following which governments are once again imposing various restrictions. At
the same time, there is a recovery trend in the volume of economic activity around the world
that leads on one hand, to significant demand for certain products and services and on the
other hand, disruptions to worldwide supply chain routes and some raw materials. The Group
continues to take measures to ensure the health and safety of its employees, suppliers, other
business partners and the communities in which it operates in order to ensure, among others,
the operation level, the proper functioning of its facilities and to minimize the pandemic’s
potential impact on its business. Manufacturing continues at the Group’s sites without
interruptions. However, there is still a difficulty in assessing the future impacts of the
pandemic on the Group’s operations, inter alia, in light of the uncertainty of its
duration, the extent of its intensity and effects on global supply chains and global markets,
and additional countermeasures that may be taken by governments and central banks. |
The
Group face a number of risks, including uncertainties regarding finalization of the development process, demand and market acceptance
of the Group’s products, the effects of technological changes, competition and the development of products by competitors. Additionally,
other risk factors also exist, such as the ability to manage growth and the effect of planned expansion of operations on the Group’s
future results. In addition, the Group expects to continue incurring significant operating costs and losses in connection with the development
of its products and increased marketing efforts. As mentioned above, the Group has not yet generated significant revenues from its operations
to fund its activities, and therefore the continuance of its activities as a going concern depends on the receipt of additional funding
from its current stockholders and investors or from third parties.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION
The
financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP).
Principles
of Consolidation
The
consolidated financial statements are prepared in accordance with US GAAP. The consolidated financial statements of the Company include
the Company and its wholly-owned and majority-owned subsidiaries. All inter-company balances and transactions have been eliminated.
Use
of Estimates
The
preparation of unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the
United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, certain
revenues and expenses, and disclosure of contingent assets and liabilities as of the date of the financial statements. Actual results
could differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate
to the going concern assumptions, stock based compensation and estimations in respect of service period upon issuance of shares to services
providers.
Functional
Currency and Foreign Currency Translation and Transactions.
Effective
January 1, 2020, the Company adopted the US dollar as its functional currency. Prior to January 1, 2020, the functional currency of the
Company was the New Israeli Shekel (“NIS”). The change in functional currency of the Company is due to the increased exposure
to the US dollar as a result of the currency in the primary economic environment in which the Israeli subsidiary operates is the USD.
Therefore,
the currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the US
dollar.
Transactions
denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing
at the dates of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the exchange
rate prevailing at the balance sheet date. Non-monetary assets and liabilities are translated using the historical rate on the date of
the transaction. All exchange gains or losses arising from translation of these foreign currency transactions are included in net loss
for the year ended As of December 31, 2021 and 2020.
Cash
and cash equivalents
Cash
equivalents are short-term highly liquid investments which include short term bank deposits (up to three months from date of deposit),
that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the
date acquired.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Property,
plant and equipment, net
| 1. | Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated
using the straight-line method over the estimated useful lives of the assets. When an asset
is retired or otherwise disposed of, the related cost and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition
is reflected in the Statements of Operations and Comprehensive Loss. |
SCHEDULE OF RATE OF DEPRECIATION
| |
% | |
| |
| |
Computers and software | |
| 33 | |
Furniture and office equipment | |
| 6 – 15 | |
Impairment
of long-lived assets
The
Group’s long-lived assets are reviewed for impairment in accordance with Accounting Standards Codification (“ASC”)
Topic 360, “Property, Plant and Equipment”, whenever events or changes in circumstances indicate that the carrying amount
of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of
an asset to the future undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the
impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.
Leases
The
Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”)
assets, other current liabilities, and operating lease liabilities in our consolidated balance sheets.
ROU
assets represent Company’s right to use an underlying asset for the lease term and lease liabilities represent Company’s
obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date
based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, the Company
generally uses the incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term
of the lease payments at commencement date. The operating lease ROU asset also includes any lease payments made and excludes lease incentives.
Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise
that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Stock-based
compensation
The
Company measures and recognizes the compensation expense for all equity-based payments to employees based on their estimated fair values
in accordance with ASC 718, “Compensation-Stock Compensation”. Share-based payments including grants of stock options are
recognized in the statement of comprehensive loss as an operating expense based on the fair value of the award at the date of grant.
The fair value of stock options granted is estimated using the Black-Scholes option-pricing model. The Company has expensed compensation
costs, net of estimated forfeitures, applying the accelerated vesting method, over the requisite service period or over the implicit
service period when a performance condition affects the vesting, and it is considered probable that the performance condition will be
achieved.
Share-based
payments awarded to consultants (non-employees) are accounted for in accordance with ASC Topic 505-50, “Equity-Based Payments to
Non-Employees”.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Deferred
income taxes
The
Group accounts for income taxes in accordance with ASC Topic 740, “Income Taxes”. Accordingly, deferred income taxes are
determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting
and the tax bases of assets and liabilities under the applicable tax law. Deferred tax balances are computed using the enacted tax rates
expected to be in effect when these differences reverse. Valuation allowances in respect of deferred tax assets are provided for, if
necessary, to reduce deferred tax assets to amounts more likely than not to be realized.
The
Group accounts for uncertain tax positions in accordance with ASC Topic 740-10, which prescribes detailed guidance for the financial
statement recognition, measurement and disclosure of uncertain tax positions recognized in an enterprise’s financial statements.
According to ASC Topic 740-10, tax positions must meet a more-likely-than-not recognition threshold. The Company’s accounting policy
is to classify interest and penalties relating to uncertain tax positions under income taxes, however the Company did not recognize such
items in its fiscal 2021 and 2020 financial statements and did not recognize any liability with respect to an unrecognized tax position
in its balance sheets.
Revenue
recognition
Revenue
is recognized only when all of the following conditions have been met: (i) there is persuasive evidence of an arrangement; (ii) delivery
has occurred; (iii) the fee is fixed or determinable; and (iv) collectability of the fee is reasonably assured. The Company usually sells
its software licenses as part of an overall solution offered to a customer that combines the sale of software licenses.
Research
and development expenses
Research
and development expenses are charged to operations as incurred.
Basic
and diluted loss per ordinary share
Basic
loss per ordinary share is computed by dividing the loss for the period applicable to ordinary shareholders, by the weighted average
number of shares of common stock outstanding during the period. Securities that may participate in dividends with the shares of common
stock (such as the convertible preferred) are considered in the computation of basic loss per share under the two-class method. However,
in periods of net loss, only the convertible preferred shares are considered, since such shares have a contractual obligation to share
in the losses of the Company.
In
computing diluted loss per share, basic loss per share is adjusted to reflect the potential dilution that could occur upon the exercise
of potential shares. Accordingly, in periods of net loss, no potential shares are considered.
Concentrations
of credit risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents as well
as certain other current assets that do not amount to a significant amount. Cash and cash equivalents, which are primarily held in Dollars
and New Israeli Shekels, are deposited with major banks in Israel and United States. Management believes that such financial institutions
are financially sound and, accordingly, minimal credit risk exists with respect to these financial instruments. The Company does not
have any significant off-balance-sheet concentration of credit risk, such as foreign exchange contracts, option contracts or other foreign
hedging arrangements.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars)
NOTE
2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION (cont.)
Contingencies
The
Company records accruals for loss contingencies arising from claims, litigation and other sources when it is probable that a liability
has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional
information becomes available. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recent
Accounting Pronouncements
Accounting
Pronouncements Not Yet Adopted
In
December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in
this ASU simplify the accounting for income taxes, eliminates certain exceptions to the general principles in Topic 740 and clarifies
certain aspects of the current guidance to improve consistent application among reporting entities. ASU 2019-12 is effective for fiscal
years beginning after December 15, 2021 and interim periods within annual periods beginning after December 15, 2022, though early adoption
is permitted, including adoption in any interim period for which financial statements have not yet been issued. The Company is currently
evaluating the effect the adoption of ASU 2019-12 will have on its consolidated financial statements.
In
August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and
Hedging Contracts in Entity s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity s Own
Equity. ASU 2020-06 will simplify the accounting for convertible instruments by reducing the number of accounting models for
convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion
features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to
be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host
contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2)
convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06
also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce
form-over-substance-based accounting conclusions. ASU 2020-06 will be effective for public companies for fiscal years beginning
after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than
fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently
evaluating the impact that the adoption of ASU 2020-06 will have on the Company’s consolidated financial statement
presentation or disclosures.
Other
new pronouncements issued but not effective as of December 31, 2021 are not expected to have a material impact on the Company’s
consolidated financial statements.
NOTE
3 – OTHER CURRENT ASSTES
SCHEDULE
OF OTHER CURRENT ASSETS
| |
| | | |
| | |
| |
December 31, | |
| |
2021 | | |
2020 | |
Related Parties | |
| 7,185 | | |
| - | |
Government Institutions | |
| 7,010 | | |
| 8,356 | |
Other Receivable | |
| 53,645 | | |
| 33,822 | |
Other
Current Assets | |
| 67,840 | | |
| 42,178 | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE
4 – PROPERTY AND EQUIPMENT, NET
SCHEDULE
OF PROPERTY AND EQUIPMENT, NET
| |
| | | |
| | |
| |
December 31, | |
| |
2021 | | |
2020 | |
Computers | |
| 70,475 | | |
| 61,538 | |
Furniture and office equipment | |
| 16,454 | | |
| 16,454 | |
Property and equipment, gross | |
| 86,929 | | |
| 77,992 | |
Less - accumulated depreciation | |
| (59,152 | ) | |
| (51,938 | ) |
Total property and equipment, net | |
| 27,777 | | |
| 26,054 | |
In
the years ended December 31, 2021 and 2020, depreciation was US$ 7,214
and US$14,587
respectively.
In the years
ended December 31, 2021 and 2020, the Company acquired fixed assets in the amounts of US$ 8,931 and US$24,232 respectively.
NOTE
5 –OTHER ACCOUNTS LIABILITIES
SCHEDULE
OF OTHER ACCOUNTS LIABILITIES
| |
| | | |
| | |
| |
December 31, | |
| |
2021 | | |
2020 | |
Employees and related institutions | |
| 261,455 | | |
| 227,760 | |
Accrued expenses and other liabilities | |
| 249,333 | | |
| 90,501 | |
Deferred revenues | |
| 7,600 | | |
| 11,381 | |
Related parties | |
| 120,000 | | |
| 167,232 | |
Other
Accounts Liabilities | |
| 638,388 | | |
| 496,874 | |
NOTE
6 – LEASES
In
December 16, 2020 the Company signed a lease agreement effective as from January 1, 2021, for office space in Herzliya, Israel for a
period of 4 years
with monthly payments of approximately $5,500
(NIS 17,000) and an option to extend the agreement
for an additional 1 year
with monthly payments of approximately $5,900
(NIS 18,275).
As of December 31, 2021, the balance of the lease liability amounted to $218,983
and right-of-use asset amounted to $201,518.
| A. | The
components of operating lease cost for the year ended December 31, 2021 and 2020 were as
follows: |
SCHEDULE
OF LEASE COST
| |
| | |
| |
| |
December 31, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Operating lease costs | |
| 63,134 | | |
| 29,173 | |
Short-term lease cost | |
| 6,709 | | |
| - | |
Total operating lease cost | |
| 69,843 | | |
| 29,173 | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE
6 – LEASES (continue)
| B. | Supplemental
cash flow information related to operating leases was as follows: |
SCHEDULE
OF SUPPLEMENTAL CASH FLOW INFORMATION TO OPERATING LEASES
| |
| | | |
| | |
| |
December 31, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Cash paid for amounts included in the measurement of lease liabilities: | |
| | | |
| | |
Cash flows from operating leases | |
| 63,134 | | |
| 29,173 | |
Right-of-use assets obtained in exchange for lease obligations (non-cash): | |
| | | |
| | |
Operating leases | |
| 242,906 | | |
| - | |
| C. | Supplemental
balance sheet information related to operating leases was as follows: |
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET
INFORMATION TO OPERATING LEASES
| |
December 31, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Operating leases: | |
| | | |
| | |
Operating leases right-of-use asset | |
| 201,518 | | |
| - | |
| |
| | | |
| | |
Current operating lease liabilities | |
| 45,756 | | |
| - | |
Non-current operating lease liabilities | |
| 173,227 | | |
| - | |
Total operating lease liabilities | |
| 218,983 | | |
| - | |
| |
| | | |
| | |
Weighted average remaining lease term (years) | |
| 4 | | |
| - | |
| |
| | | |
| | |
Weighted average discount rate | |
| 10 | % | |
| - | |
| D. | Future
minimum lease payments under non-cancellable leases as of December 31, 2021 were as follows: |
SCHEDULE
OF FUTURE MINIMUM LEASE PAYMENTS
| |
| | |
| |
2021 | |
| |
| |
2022 | |
| 65,595 | |
2023 | |
| 65,595 | |
2024 | |
| 65,595 | |
2025 | |
| 70,514 | |
Total operating lease payments | |
| 267,299 | |
Less: imputed interest | |
| 48,316 | |
Present value of lease liabilities | |
| 218,983 | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE
7 – COMMITMENTS AND CONTINGENCIES
On
October 27, 2020 WHEN filed suit in State Court, Palm Beach County, Florida, against FSC Solutions, Inc. (“FSC”), Eli Gal
Levy (“EL”) and Padem Consultants Sprl (collectively, the “Defendants”). The lawsuit relates to the Stock Purchase
Agreement entered into by WHEN with FSC and its shareholders, which included EL, pursuant to which WHEN acquired all of the issued and
outstanding stock of FSC in exchange for the issuance of 70 billion shares of WHEN unregistered common stock. FSC was the putative owner
of a software and trading platform which WHEN intended to use to enter into the on-line trading business. Subsequent to the completion
of the acquisition, we determined that FSC did not have control over the trading platform and software we expected to acquire and operate.
The Florida lawsuit seeks a declaratory judgment to unwind the FSC transaction and cancel the shares of WHEN common stock issued in the
FSC transaction that are still outstanding.
A
hearing was set for January 6, 2021 whereupon mediation was ordered. The Company and EL were in discussions to resolve this issue but
no resolution was reached. The Florida lawsuit is currently pending.
On
or about, January 19, 2022, EL filed a lawsuit in the Delaware Court of Chancery seeking to remove the restrictive legend from all the
shares of Common Stock held by EL (the “2022 Lawsuit”), which are approximately 23,000,000,000 shares. The Company retained
the services of Delaware counsel and has moved to dismiss or stay the 2022 Lawsuit in favor of the previously filed Florida lawsuit,
which involves the same parties and same issues. The Company’s motion is currently pending in the Delaware Court of Chancery.
NOTE
8 – SHAREHOLDERS’ EQUITY
Description
of the rights attached to the Shares in the Company:
Common
stock:
On
October 7, 2021, the Company filed an amendment (the “Amendment”) to its Certificate of Incorporation, as amended, to increase
the Company’s authorized share capital and to change the par value of the Company’s Common Stock. The Amendment increased
the Company’s authorized share capital to 750,000,000,000 shares of common stock (from 110,000,000,000 shares) and changed the
par value of the common stock to $0.00001 per share (from $0.0007). The Amendment was effective retroactive to September 28, 2021.
As
of December 31, 2021, there were 488,499,407,996
shares of Common Stock issued and outstanding.
Each
share of common stock entitles the holder to one vote, either in person or by proxy, at meetings of stockholders. The holders are not
permitted to vote their shares cumulatively. Accordingly, the stockholders of the Company’s common stock who hold, in the aggregate,
more than fifty percent of the total voting rights can elect all of the directors and, in such event, the holders of the remaining minority
shares will not be able to elect any of such directors. The vote of the holders of a majority of the issued and outstanding shares of
common stock entitled to vote thereon is sufficient to authorize, affirm, ratify or consent to such act or action, except as otherwise
provided by law.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE 8 – SHAREHOLDERS’
EQUITY (continue)
SERIES
A PREFERRED STOCK
The
Company has authorized 10,000,000 Series A Preferred Stock $0.0007 par value per share (the “Preferred Stock Series A”).
As of December 31, 2021, and 2020, there are 5,000,000 shares of Preferred Stock Series A outstanding.
The
Preferred Stock Series A have the right to vote with the Common Stock on all matters. Each share of Preferred Stock Series A has 10,000
votes per share. Each of George Baumoehl and Gaya Rozensweig, the directors of the Company, hold 2,500,000 shares of the Preferred Stock
Series A.
SERIES
B PREFERRED STOCK
The
Company has authorized 3,870,000 Series B Convertible Preferred Stock $0.0007 par value per share (the “Preferred Stock Series
B”). As of December 31, 2020, there are 3,870,000 shares of Preferred Stock Series B outstanding.
The
Preferred Stock Series B are held by UCG, the principal shareholders of the Company. The principal’s shareholders of UCG are George
Baumoehl and Gaya Rozensweig, the directors of the Company.
The
Preferred Stock Series B were issued to UCG as consideration for the Merger. Each share of the Series B Preferred Shares will convert
into 100,000 shares of WHEN’s common stock, par value $0.0007 (the “Common Stock”), for an aggregate amount of 387,000,000,000
shares of WHEN’s Common Stock, upon the filing with the Secretary of State of Delaware of an amendment to WHEN’s certificate
of incorporation increasing the number of authorized shares of Common Stock that the Company is authorized to issue from time to time.
TRANSACTIONS
Following
the effectiveness of the Amendment referred to in above, On December 3, 2021, the Company issued 387,000,000,000
shares of the Company’s common stock to
UCG, Inc. upon the automatic conversion of all 3,870,000
outstanding shares of the Company’s Series
B Preferred Shares issued in April 2020 in connection with the acquisition of RNA, Ltd. From UCG, Inc.
On
August 31, 2021 the Company issued 500,000,000
shares of common stock, par value $0.00001,
to its legal advisor in respect of consulting services related to assisting the Company with its follow-on-offering registration statements,
which, as of December 31, 2021, is expected to be provided until December 31, 2022. The Company estimated the fair value of the shares
issued based on the share price at the agreement date (which was $0.0005),
at $250,000
thousand of which $69,444
were recorded as share based compensation
expenses in the year ended December 31,2021, and the remaining $180,556, were recorded as prepaid expense under Other Current
Assets and will be expensed over the estimated remaining consulting services. Per the agreement, the Company committed to pay the
Consultant additional $350,000 only
in the event that the Company raises at least $5 million in the follow-on-offering in a senior security exchange.
Between
August and October 2021, the Company and certain investors entered into subscription agreements for a private placement of units of the
Company securities (the 2021 Private Placements”) where each unit (a “Unit” and collectively the “Units”)
is comprised of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional
share of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price
per unit is $0.0001. Subscription agreements for an aggregate of $900,000 provide that the investors are to remit the subscription proceeds
at the time of investment and in three month intervals thereafter, in each case in amounts equal to 20% of their committed amounts. Subscription
agreements for a total of $386,000 were remitted at the time of execution. Through December 31, 2021, the Company received a total of
$386,000 from these subscription proceeds and in consideration thereof issued 3,860,000,000 shares of Common Stock and warrants for an
additional 3,860,000,000 shares of Common Stock.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE 8 – SHAREHOLDERS’
EQUITY (continue)
On
November 10, 2021, the Company entered into an agreement with a consultant with a term of 12 months under which it undertook to issue
to the Consultant restricted stock for services rendered during the initial six months, representing $150,000
value of the stock based on a 10 day moving average.
Following a public offering of its stock the Company undertook to pay to the Consultant $15,000
per month. As of December 3, 2021, the company
issued 150,000,000
shares of common stock. As of December 31,
2021 the Company recorded $42,265 as general and administrative expenses and the remaining $107,735 were recorded as prepaid expenses
under Other Current Assets.
On
November 11, 2022, the Board of Director of the Company approved the issuance of 1,500,000,000
share of common stock of the Company $0.0001
par value, to a principal shareholder of CrossMobile
in consideration for his efforts to complete the CrosssMobile transaction (see Note 15). The Company estimated the value of the shares
issued based on the share price of the Company as of the date of the agreement at $900,000 and recorded such value prepaid transaction
costs under Other Current Assets.
On
December 3, 2021 the Company issued 5,700,000,000 shares of common stock, par value $0.00001, to a consultant in respect of business
development consulting services. The Company estimated the fair value of the shares issued at $1,290,000 thousand which were recorded
as share based compensation expenses in the year ended December 31, 2021.
NOTE
9 - STOCK OPTIONS
On
June 21, 2021, the board of directors of the Company approved the 2021 Equity Incentive Plan (the “2021 Plan”) pursuant to
which the Company may issue awards, from time to time, consisting of non-qualified stock options, restricted stock grants and restricted
stock units. In addition, stock option awards that qualify under Section 102 of the Israeli Tax Ordinance (New Version) 1961 (the “ITO”),
and/or under Section 3(i) of the ITO, may be granted.
On
June 28, 2021, the Board of Directors of the Company approved the issuance of options to purchase 6,800,000,000 shares of the Company’s
Common Stock with an exercise price of $0.0001, to three members of its advisory board, under the Company’s 2021 Plan. Options
to purchase 1,700,000,000 shares of Common Stock shall vest on the first anniversary of the agreement and the remaining options shall
vest quarterly, over additional 3 years. The grant is subject the approval of the Board of Directors of the Company.
The
fair value of the options was determined using the Black-Scholes pricing model, assuming a risk free rate of 0.27%, a volatility factor
of 342%, dividend yields of 0% and an expected life of 4 years and was estimated at $5,436,000.
The
following table presents the Company’s stock option activity during the year ended December 31, 2021:
SCHEDULE
OF COMPANY’S STOCK OPTION ACTIVITY
| |
Number of
Options | | |
Weighted Average
Exercise Price | |
| |
| | |
| |
Outstanding at December 31,2020 | |
| - | | |
| - | |
Granted | |
| 6,800,000,000 | | |
| 0.0001 | |
Exercised | |
| - | | |
| - | |
Forfeited or expired | |
| - | | |
| - | |
Outstanding at December 31, 2021 | |
| 6,800,000,000 | | |
| 0.0001 | |
Number of options exercisable at December 31, 2021 | |
| - | | |
| - | |
The
aggregate intrinsic value of the awards outstanding as of December 31, 2021 is $2,720,000.
These amounts represent the total intrinsic value, based on the Company’s stock price of $0.0005
as of December 31, 2021, less the weighted exercise
price. This represents the potential amount received by the option holders had all option holders exercised their options as of that
date.
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE
9 - STOCK OPTIONS (continue)
The
stock options outstanding as of December 31, 2021, have been separated into exercise prices, as follows:
SCHEDULE
OF STOCK OPTION OUTSTANDING RANGE OF EXERCISE PRICE
Exercise price | |
Stock
options
outstanding | | |
Weighted average
remaining
contractual
life – years | | |
Stock
options
vested | |
As of December 31, 2021 |
| |
| | |
| | |
| |
0.0001 | |
| 6,800,000,000 | | |
| 3.49 | | |
| - | |
0.001 | |
| 6,800,000,000 | | |
| 3.49 | | |
| - | |
Compensation
expense recorded by the Company in respect of its stock-based compensation awards for the year ended December 31, 2021 was $2,084,121
and are included in General and Administrative
expenses in the Statements of Operations.
NOTE
10 – RESEARCH AND DEVELOPMENT EXPENSES
SCHEDULE OF RESEARCH AND DEVELOPMENT EXPENSES
| |
| | |
| |
| |
Year ended December 31 | |
| |
2021 | | |
2020 | |
Salaries and related expenses | |
| 375,469 | | |
| 286,266 | |
Professional fees and other development costs | |
| 33,623 | | |
| 94,776 | |
Depreciation and amortization | |
| 47,630 | | |
| 35,320 | |
Vehicle maintenance | |
| 19,761 | | |
| 18,953 | |
Rent and office maintenance | |
| 20,638 | | |
| 53,895 | |
Total
Research and Development Expenses | |
| 497,121 | | |
| 489,210 | |
NOTE
11 – GENERAL AND ADMINISTRATIVE EXPENSES
SCHEDULE OF GENERAL AND ADMINISTRATIVE EXPENSES
| |
| | |
| |
| |
Year ended December 31 | |
| |
2021 | | |
2020 | |
Salaries and related expenses | |
| 222,784 | | |
| 267,036 | |
Professional services | |
| 278,221 | | |
| 139,531 | |
Rent and office maintenance | |
| 9,651 | | |
| 8,398 | |
Office expenses | |
| 91,557 | | |
| 54,750 | |
Depreciation and amortization | |
| 10,416 | | |
| 5,302 | |
Advertising | |
| 2,009 | | |
| 7,273 | |
Doubtful debts | |
| 3,994 | | |
| 12,773 | |
Other expenses | |
| 64,227 | | |
| 28,600 | |
Total
general and administrative expenses | |
| 682,859 | | |
| 523,663 | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars)
NOTE
12 – INCOME TAX
| A. | US
resident companies are taxed on their worldwide income for corporate income tax purposes
at a statutory rate of 21% this reflect certain effects of the Act which includes a reduction
in the corporate tax rate from 35% to 21% as well as other changes. No further taxes are
payable on this profit unless that profit is distributed. If certain conditions are met,
income derived from foreign subsidiaries is tax exempt in the US under applicable tax treaties
to avoid double taxation. |
Income
of the Israeli company is taxable from 2018 and onwards, at corporate tax rate of 23%.
The
Company and its Israeli Subsidiary has not received final tax assessments since its inception.
As
of December 31, 2021, the Company and its Israeli Subsidiary has carryforward losses for tax purposes of approximately $9,156,722 million
and $2,755,469 million, respectively, which can be offset against future taxable income, if any.
| B. | The
following is reconciliation between the theoretical tax on pre-tax income, at the tax rate
applicable to the Company (federal tax rate) and the tax expense reported in the financial
statements: |
SCHEDULE OF EFFECTIVE INCOME TAX EXPENSE
| |
| | |
| |
| |
Year ended December 31 | |
| |
2021 | | |
2020 | |
Pretax loss | |
| 4,596,813 | | |
| 872,793 | |
Federal tax rate | |
| 21 | % | |
| 21 | % |
Income tax computed at the ordinary tax rate | |
| (965,331 | ) | |
| (183,286 | ) |
Non-deductible expenses | |
| 9,595 | | |
| 2,423 | |
Stock-based compensation | |
| 588,865 | | |
| - | |
Tax in respect of differences in corporate tax rates | |
| (18,178 | ) | |
| (13,860 | ) |
Losses and timing differences in respect of which no deferred taxes were generated | |
| 385,049 | | |
| 194,723 | |
Income
tax expense benefit | |
| - | | |
| - | |
| C. | Deferred
taxes result primarily from temporary differences in the recognition of certain revenue and
expense items for financial and income tax reporting purposes. Significant components of
the Company’s future tax assets are as follows: |
SCHEDULE OF DEFERRED TAX ASSETS
| |
| | |
| |
| |
Year ended December 31 | |
| |
2021 | | |
2020 | |
Composition of deferred tax assets: | |
| | |
| |
Provision for employee related obligation | |
| 49,750 | | |
| 40,617 | |
Allowance for doubtful accounts | |
| 3,994 | | |
| 7,127 | |
Non capital loss carry forwards | |
| 2,561,464 | | |
| 2,182,415 | |
Valuation allowance | |
| (2,615,208 | ) | |
| (2,230,159 | ) |
Net deferred taxes | |
| - | | |
| - | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE
13 – LOSS PER SHARE OF COMMON STOCK
Basic
loss per share is computed by dividing net loss by the weighted average number of shares outstanding during the year. The weighted average
number of shares of Common Stock used in computing basic and diluted loss per ordinary share for the years ended December 31, 2021 and
2020, are as follows:
SCHEDULE OF WEIGHTED AVERAGE NUMBER OF SHARES BASIC AND DILUTED
| |
| | |
| |
| |
Year ended December 31 | |
| |
2021 | | |
2020 | |
| |
Number of shares | |
| |
| | | |
| | |
Weighted average number of shares of Common Stock outstanding attributable to ordinary shareholders | |
| 120,832,640,873 | | |
| 60,840,910,336 | |
NOTE
14 – RELATED PARTIES
SCHEDULE OF RELATED PARTY EXPENSES
| A. | Transactions
and balances with related parties |
| |
2021 | | |
2020 | |
| |
Year ended December 31, | |
| |
2021 | | |
2020 | |
General and administrative expenses: | |
| | | |
| | |
Salaries and fees to officers (*) | |
| 1,974,893 | | |
| 106,247 | |
(*) of which share based compensation | |
| 1,838,930 | | |
| - | |
| |
| | | |
| | |
Research and development expenses: | |
| | | |
| | |
Salaries and fees to officers | |
| 86,148 | | |
| 61,532 | |
| B. | Balances
with related parties and officers: |
| |
As of December 31, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Other current assets | |
| 7,186 | | |
| - | |
Other accounts liabilities | |
| 120,000 | | |
| 179,613 | |
Liability for employee rights upon retirement | |
| 213,371 | | |
| 95,451 | |
Long term loan from related party | |
| 2,012,339 | | |
| 1,812,704 | |
WORLD
HEALTH ENERGY HOLDINGS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S.
dollars except share and per share data)
NOTE 14 – RELATED PARTIES (continue)
| C. | On
October 21, 2020, RNA Ltd., the Company’s subsidiary, and Giora Rozensweig, the Company’s
interim Chief Executive Officer, entered into an employment agreement providing for the employment
(the “Giora Employment Agreement”) of Mr. Giora Rozensweig as RNA’s Chief
Executive Officer, with retroactive application to July 1, 2020. Under the Giora Employment
Agreement, Mr. Rozensweig is paid an annual gross salary of the current New Israeli
Shekel equivalent of $133,500,
payable monthly. Under
the Giora Rozensweig Employment Agreement he also receives the following: (i) Manager’s
Insurance under Israeli law for the benefit of Mr. Rosenzweig pursuant to which RNA contributes
amounts equal to (a) 8-1/3 percent (and Mr. Rosenzweig contributes an additional 5%) of each
monthly salary payment, and (b) 6.5% of Mr. Rosenzweig’s salary (with Mr. Rosenzweig
contributing an additional 6%) to a pension fund, a form of deferred compensation program
established under Israeli law.
The Giora Employment Agreement also contains certain provisions for termination by RNA, which
may result in a severance payment equal to twenty four months of base salary then in effect. |
| D. | On
October 21, 2020, RNA Ltd., the Company’s subsidiary, and Gaya Rozensweig entered into
an employment agreement providing for the employment (the “Gaya Employment Agreement”)
of Ms. Gaya Rozensweig as RNA’s controller, with retroactive application to July 1,
2020. Under the Gaya Employment Agreement, Ms. Rozensweig is paid an annual gross
salary of the current New Israeli Shekel equivalent of $93,500,
payable
monthly. Under
the Rosenzweig Employment Agreement, she also receives the following: (i) Manager’s
Insurance under Israeli law for the benefit of Ms. Rosenzweig pursuant to which RNA contributes
amounts equal to (a) 8-1/3 percent (and Ms. Rosenzweig contributes an additional 5%) of each
monthly salary payment, and (b) 6.5% of Ms. Rosenzweig’s salary (with Ms. Rosenzweig
contributing an additional 6%) to a pension fund, a form of deferred compensation program
established under Israeli law.
The Gaya Employment Agreement also contains certain provisions for termination by RNA, which
may result in a severance payment equal to twenty four months of base salary then in effect. |
| E. | Giora
Rozensweig and our subsidiary SG entered into an Irrevocable License and Royalty Agreement
as of December 31, 2020 pursuant to which Mr. Rozensweig granted to SG an irrevocable worldwide
license to certain technologies and the related intelelctual rights. In consideration of
such license, Mr. Rozensweig is entitled to 1.5%
of annual gross revenues, payable on a quarterly basis and only at such time as the aggregate
gross revenues exceed $120,000. |
WORLD HEALTH ENERGY HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(U.S. dollars except share
and per share data)
NOTE
15 – SUBSEQUENT EVENTS
|
1. |
CrossMobile
investment agreement |
On
March 22, 2022 the Company, CrossMobile S.P.Zoo, a company formed under the laws of Poland (“CrossMobile”) and the
shareholders of CrossMobile (of which Mr. Giora Rosenzweig, holds 40.67% and Mr. George Baumeohl holds 6.67%, of the issued preferred share capital of CrossMobile), entered into an Investment Agreement (the “Agreement”) pursuant to which the Company is to
purchase 26%
of the outstanding common share capital of CrossMobile on a fully diluted basis, in consideration of the issuance by the Company to
CrossMobile of 10,000,000,000
restricted shares of Company common stock (the “Initial Investment”). The acquisition is subject to the registration
with the Polish Companies Registrar of the shares issuable to the Company in respect of the Initial Investment, as required under
local law. Upon the registration of the Company shareholdings in CrossMobnile, the closing of the Initial Investment will be deemed
to have occurred and the 10,000,000,000
Company shares of common stock will be issued to CrossMobile.
CrossMobile
is a licensed mobile virtual network operator (“MVNO”) in Poland, providing the necessary licenses and key
infrastructure in the EU. With its involvement in CrossMobile, the Company expects to provide advanced cybersecurity solutions and
other next-generation value-added services to CrossMobile’s future product offerings.
In
addition, for 18 months following the date of the Agreement, the Company has the option to purchase additional shares of CrossMobile,
such that following such additional purchase, the Company shall hold approximately 51% of CrossMobile’s outstanding share capital
on a fully diluted basis. In the event the Company shall choose to exercise the option, the Company shall issue such number of restricted
shares of common stock of the Company calculated based on pre-money valuation of CrossMobile as determined by an independent appraiser
agreed between the Company and CrossMobile.
Under
the Agreement, upon the closing of the Initial Investment, Giora Rosenzweig, is to be appointed to the CrossMobile board of directors.
The Agreement provides that either party may terminate the Agreement and the transactions is the Initial Investment has not closed by
September 30, 2022.
The preferred share capital of
CrossMobile provides certain privileges, including the right to participate in CrossMobile shareholder meetings at a rate of two
votes for each preferred share and preference as to distribution of dividends at a rate equal to twice the dividends distributed to
the holders of the common shares in CrossMobile.
|
2. |
Mr. Tromer, the CEO of CrossMobile, was appointed to the Company’s advisory board in February
2022. In connection with his service on the advisory board, on February 14, 2022, he was awarded options under the Company’s
2021 Equity Incentive Plan to purchase 6,000,000,000
shares of the Company’s common stock, at a per share exercise price of $0.0001
per share, which the exercise price for all grants to date to member of the Company’s advisory board. Mr. Tromer’s
options vest as follows: 25%
(i.e., 1,500,000,000)
option shares vest on the first anniversary of the appointment to the advisory board and the balance in increments of 400,000,000
shares on each subsequent three (3) month anniversary. |
|
3. |
On January 1, 2022, the Company
granted options to purchase 400,000,000
shares of the Company’s Common Stock
to a member of its advisory board, under the Company’s 2021 Plan. Options to purchase 100,000,000
shares of Common Stock shall vest on the
first anniversary of the agreement and the remaining options shall vest quarterly, over additional 3
years. |
|
4. |
During February 2022,
the Company and certain investors entered into subscription agreements for a private placement of units of the Company securities
in an aggregated amount of $500,000, where each unit (a “Unit” and collectively the “Units”) is comprised
of (i) one (1) share of the Company’s Common Stock and (ii) one common stock purchase warrant to purchase an additional share
of the Company’s Common Stock through the second anniversary thereof at a per share exercise price of $0.0002. The price per
unit is $0.0001. As part of the subscription agreements, CrossMobile undertook to issue the investors up to 5% of the issued and
outstanding share capital of CrossMobile. |